Section 3 of 6
Product information and disease description
543 evidence topics · 229 sources
Product description
Phase of product development
Regulatory status: Submission planned; NDA submission planned for 2027
Launch: Anticipated in 2028
OPERA-01 top-line data expected in the first quarter of 2027 (November 2026)
OPERA-01 enrollment completed and top-line timing moved to the first quarter of 2027 (August 2026)
Earlier guidance: top-line data in fall 2026 and launch in 2027 (May 2026)
Earlier guidance: top-line data in fall 2026, NDA in 2027, and approval and launch in late 2027 (March 2026)
Earlier guidance: top-line data in the second half of 2026 (August 2025)
Earlier guidance: top-line data in 2026 and launch in 2027 (May 2025)
Earlier guidance: top-line data in 2026 (December 2024)
Fast Track designation, July 2022
Fast Track designation: eligibility for priority review, accelerated approval, and rolling submission
Dose of 90 mg once daily selected in alignment with FDA, May 2025
OPERA-01: first participant dosed in November 2023
OPERA-02: initiated in the third quarter of 2025
OPERA-02: enrollment ongoing, November 2026
Partnership: Novartis clinical collaboration for ribociclib and alpelisib combinations (2020, amended 2022 and 2023)
Partnership: Novartis ribociclib supply for OPERA-02 (2024)
Partnership: Pfizer palbociclib (2020) and atirmociclib (2025) agreements
Patents: composition of matter to 2036; pending applications to 2040 to 2046
Regulatory status outside the United States
No evidence found.
Product information
Generic, brand name and therapeutic class of product
Development code and nonproprietary name
Brand name
No evidence found.
Therapeutic class: complete estrogen receptor antagonist and selective estrogen receptor degrader
“Here, we describe our discovery of the investigational drug OP-1250 (palazestrant). OP-1250 is a potent complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) that is active in both WT and mutESR1 breast cancer tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International nonproprietary name: proposed in 2022
“Proposed INN: List 128” (opens the source at this quote in a new tab)
“palazestrantum” (opens the source at this quote in a new tab)
“antiestrogen, antineoplastic” (opens the source at this quote in a new tab)
“C28H36FN3O” (opens the source at this quote in a new tab)
“2092925-89-6” (opens the source at this quote in a new tab)
Dosage forms and strengths
Commercial dosage form and strength
No evidence found.
Capsules given fasted in the phase 1/2 monotherapy study
“All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles. In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Capsule formulation and gastrointestinal events; tablet formulation in ongoing studies
“the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events. Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tablet formulation in OPERA-01
Capsules in the ribociclib combination analysis
Doses in the phase 3 trials: 90 mg and 120 mg once daily in OPERA-01 Part 1; 90 mg once daily in OPERA-02
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
AHFS class
No evidence found.
WHO ATC code
No evidence found.
WHO INN classification: antiestrogen, antineoplastic
NCI Thesaurus: complete estrogen receptor antagonist
Indication
Approved indication
No evidence found.
Indication sought in the planned NDA: monotherapy in second- and third-line ER+/HER2- metastatic breast cancer
Population of the pivotal trial OPERA-01
Second indication under study: first line in combination with ribociclib
Pharmacology
Mechanism of action
Complete estrogen receptor antagonist and selective estrogen receptor degrader
“Palazestrant (OP-1250) is a novel oral, complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD) that acts by blocking both transcriptional activation function domains, AF1 and AF2, required for the estradiol-generated transcriptional activity of ER” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blockade of AF1 and AF2 compared with selective estrogen receptor modulators
“Selective estrogen receptor modulators (SERMs) block only the AF2 domain, leaving the AF1 domain active and capable of gene transcription. Palazestrant is a complete ER antagonist (CERAN) and selective ER degrader (SERD) that acts by blocking both AF1 and AF2 domains to completely block ER-driven transcriptional activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for blocking both activation functions
Inhibition of AF1-dependent activity in uterine cells
“Elacestrant demonstrated partial agonist activity, with maximum response of 24%; imlunestrant, fulvestrant, and OP-1250 did not induce measurable AP activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“imlunestrant, fulvestrant, and OP-1250 completely inhibited activity with IC50 values of 32, 9.4, and 6.4 nmol/L, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estrogen receptor degradation in breast cancer cells
“OP-1250 degrades ERα with comparable potency to fulvestrant (DC50 0.52 nmol/L and 0.56 nmol/L, respectively; Emax 62% and 69%, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OP-1250 treatment reduced ERα protein levels by 63% relative to vehicle in MCF7 and 72% in CAMA-1 cells” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proteasome-dependent degradation
“In MCF7 cells, degradation of ERα by OP-1250 was observed as early as 2 hours after treatment, levels reduced in a time-dependent manner, and degradation was blocked by treatment with the proteasome inhibitor MG-132” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antagonism of residual receptor after degradation
“Palazestrant promotes ER degradation at levels similar to that of fulvestrant and greater than that of elacestrant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the presence of residual ER protein has been detected in vitro with these treatments” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, palazestrant demonstrates robust CERAN activity that completely blocks ER-induced transcription, ensuring full inhibition of any residually available ER remaining from its SERD activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Receptor selectivity
“OP-1250 demonstrated no agonist-like cross-reactivity on glucocorticoid, progesterone, or androgen receptors. Inhibition of agonist-induced androgen receptor transcriptional activity was detected only at >1 μmol/L OP-1250” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Activity against ESR1 Y537S and D538G mutant receptors
“In AP assays conducted with mutant Ishikawa cells, OP-1250 displayed favorable potency against both mutants, comparable to that of fulvestrant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both AP and proliferation assays, CERANs showed reduced potency in the mutant cell lines relative to wild-type.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antiproliferative potency in estrogen-stimulated cells
Corepressor NCoR1 recruitment
Earlier hypothesis for AF1 inhibition
“While the mechanism of AF1 inhibition by CERANs such as OP-1250 has not been determined, we hypothesize that this may occur through recruitment of ER corepressor proteins such as NCoR, as suggested previously” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Reduction of ESR1 variant mutations in circulating tumor DNA
Clinical benefit by change in ESR1 mutations
“In patients who had been treated with the RP2D of 120 mg/day palazestrant and had ctDNA available for analysis, the CBR was 73% (8/11) in patients who had a reduction in ESR1 mutations and 25% (8/32) in those who did not have a reduction in ESR1 mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ki67 and estrogen receptor expression in tumor samples
“Palazestrant treatment was associated with significantly reduced Ki67 levels from 29.2% (N = 18) to 20.4% (N = 12); P = 0.041” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“resulted in a numerical decrease in ERα Allred score from 6.67 (N = 18) to 5.17 (N = 12); P = 0.13” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Target engagement in a patient-derived xenograft
“OP-1250 reduced Ki67 levels in a dose-dependent manner, in line with observed tumor growth inhibition” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At both the 5 and 10 mg/kg doses, nuclear ERα staining was reduced by approximately 75%, compared with the vehicle group, confirming target engagement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uterine wet weight assay
“E2 and tamoxifen significantly increased UWW, while OP-1250 and fulvestrant did not. OP-1250 and fulvestrant inhibited E2-induced increases in weight, with OP-1250 displaying dose-dependent inhibition as low as 0.01 mg/kg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESR1 Y537S patient-derived xenografts
“In this model, OP-1250 doses of ≥1 mg/kg outperformed fulvestrant, and all treatments led to tumor growth inhibition; 10 and 30 mg/kg doses led to tumor shrinkage below starting volume in all treated animals” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both OP-1250 doses outperformed elacestrant, with greatest tumor growth inhibition with 10 mg/kg OP-1250.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intracranial xenograft model
“4 of 8 animals in the OP-1250 monotherapy group and 6 of 8 in the OP-1250 + ribociclib group lacked detectable tumor at study day 100.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OP-1250 treatment (monotherapy or in combination with ribociclib) resulted in all 8 animals alive at study day 100 and 6 alive 50 days after cessation of dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical combination with CDK4/6 inhibitors
“The 10 mg/kg dose of OP-1250, which leads to plasma concentrations similar to those measured in clinical studies, outperformed 75 mg/kg monotherapy doses of both CDK4/6 inhibitors and resulted in tumor shrinkage. Combination treatment resulted in more pronounced and consistent tumor shrinkage across doses, with all but one animal achieving >50% reduction in tumor volume” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“addition of OP-1250 to either CDK4/6 inhibitor extended animal survival” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
QTcF in the phase 1/2 monotherapy study
Planned electrocardiogram analysis
Bradycardia at the recommended phase 2 dose
“TEAEs of oral SERDs observed in less than 10% of patients treated at the RP2D of palazestrant included bradycardia (9%) and photopsia (5%); all bradycardia and photopsia events were grade 1, and there were no dose modifications, interruptions, or discontinuations due to these events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bradycardia during dose escalation
QTcF in combination with ribociclib
Pharmacokinetics
Absorption and time to peak concentration
Accumulation, peak-to-trough fluctuation, and effective half-life
“Steady-state PK profiles showed limited peak-to-trough fluctuation (range, 1.89–2.51), with an accumulation ratio of approximately 3 for Cmax (range, 1.96–3.55) and of approximately 4 for AUC0–24 (range, 3.63–5.20), and an effective half-life of approximately 70 h (range, 50.5 h to 77.2 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Terminal half-life
“Overall, palazestrant showed biphasic elimination in the distribution phase, which was similar to that observed with 120 mg palazestrant in healthy volunteers (data on file), confirming the 8-day terminal half-life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distribution and support for once-daily dosing
“PK analyses showed that palazestrant was readily bioavailable and rapidly absorbed (reaching peak concentration after 4 h), with extensive tissue distribution, dose-proportional exposure, and a long half-life of approximately 8 days. These PK characteristics support once-daily dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Steady-state exposure at the recommended phase 2 dose
“The steady-state geometric mean AUC0–24 was 4030 and 9210 h*ng/mL for 60 and 120 mg dose cohorts, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the RP2D of 120 mg (n = 73), the geometric mean Cmax at steady state was 541 ng/mL, and the geometric mean Cavg was 384 ng/mL, showing sustained concentrations above the predicted efficacy threshold” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Steady-state pharmacokinetic parameters at 60, 90, and 120 mg
Posted steady-state AUC by dose in the registry results
Time to peak concentration during dose escalation
Terminal half-life and peak-to-trough variability at the dose selection analysis
Exposure at 90 mg and 120 mg in combination with ribociclib
Plasma protein binding across species
Nonclinical oral half-life
“Compound 21 is orally bioavailable and has low clearance and a long half-life in the mouse, rat, dog, and monkey” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The half-lives after a single oral dose in the mouse, rat, dog, and monkey were 10, 16, 106, and 34 h, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nonclinical single oral dose pharmacokinetics
Brain and tumor concentrations in mice
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information, boxed warning, contraindications, and REMS
Treatment-emergent and treatment-related adverse events: phase 1/2 monotherapy at 60 and 120 mg
“Most patients (95.3%) who received the RP2D of 120 mg/day experienced ≥ 1 TEAE of any grade, most commonly nausea (62.8%), vomiting (29.1%), and fatigue (25.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3 TEAEs were reported in 21 (24.4%) patients, most commonly vomiting (n = 4 [4.7%]), neutropenia, nausea, and fatigue (n = 3 each [3.5%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eight (9.3%) patients treated with 120 mg/day palazestrant also experienced grade 4 TEAEs, including neutropenia (n = 6), acute respiratory failure (n = 1), and 1 patient experienced 3 grade 4 events (pulmonary embolism, diverticulitis, and acute left ventricular failure).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events by dose: posted registry results of the phase 1/2 trial
| Adverse event, affected/at risk (%) | 60 mg QD | 90 mg QD | 120 mg QD | 300 mg QD |
|---|---|---|---|---|
| Total serious adverse events | “4/33 (12.12%)” | “2/6 (33.33%)” | “16/83 (19.28%)” | “2/7 (28.57%)” |
| Febrile neutropenia (serious) | “0/33 (0.00%)” | “0/6 (0.00%)” | “2/83 (2.41%)” | “1/7 (14.29%)” |
| Nausea | “14/33 (42.42%)” | “2/6 (33.33%)” | “55/83 (66.27%)” | “6/7 (85.71%)” |
| Vomiting | “5/33 (15.15%)” | “1/6 (16.67%)” | “24/83 (28.92%)” | “5/7 (71.43%)” |
| Diarrhoea | “6/33 (18.18%)” | “0/6 (0.00%)” | “14/83 (16.87%)” | “1/7 (14.29%)” |
| Fatigue | “13/33 (39.39%)” | “0/6 (0.00%)” | “24/83 (28.92%)” | “4/7 (57.14%)” |
| Neutrophil count decreased | “2/33 (6.06%)” | “0/6 (0.00%)” | “16/83 (19.28%)” | “2/7 (28.57%)” |
| Alanine aminotransferase increased | “0/33 (0.00%)” | “0/6 (0.00%)” | “11/83 (13.25%)” | “1/7 (14.29%)” |
| Aspartate aminotransferase increased | “0/33 (0.00%)” | “0/6 (0.00%)” | “13/83 (15.66%)” | “0/7 (0.00%)” |
| Sinus bradycardia | “0/33 (0.00%)” | “0/6 (0.00%)” | “7/83 (8.43%)” | “2/7 (28.57%)” |
| Photopsia | “0/33 (0.00%)” | “2/6 (33.33%)” | “5/83 (6.02%)” | “3/7 (42.86%)” |
Neutropenia: phase 1/2 monotherapy
“Treatment-related grade 4 neutropenia occurred in 5 (5.8%) patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 6 patients with grade 4 neutropenia, 3 events resolved with a dose interruption (1 week) followed by a dose reduction (to 60 mg/day in 1 patient and to 90 mg/day in 2 patients); these patients continued treatment with no further neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While grade 4 neutropenia events occurred approximately 6-8 weeks after initiation of palazestrant, these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors, and following dose reductions, 3 patients were able to continue palazestrant with no further recurrences of neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mechanism underlying neutropenia is unknown, and no corresponding trends were observed in preclinical studies of palazestrant (unpublished data).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neutropenia, albeit at a lower frequency, has also been reported with fulvestrant, with grade ≥ 3 neutropenia observed in 1% to 2% of patients receiving fulvestrant monotherapy and rates of febrile neutropenia of 0 to 1% [30, 31].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neutropenia: blood count monitoring in ongoing trials
“All ongoing studies with palazestrant include proactive monitoring of blood counts that is more frequent during first 6–8 weeks after initiation of palazestrant, with the possibility for dose reduction or interruption following the detection of grade 3 or 4 neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events including neutropenia: combination with ribociclib
| Related TEAE, n (%) | 120 mg + ribociclib, all grades (n = 56) | 120 mg, grade 3 | 120 mg, grade 4 | 90 mg + ribociclib, all grades (n = 16) | 90 mg, grade 3 | 90 mg, grade 4 |
|---|---|---|---|---|---|---|
| Neutropenia | “47 (84%)” | “28 (50%)” | “5 (9%)” | “13 (81%)” | “9 (56%)” | “2 (16%)” |
| WBC decrease | “24 (43%)” | “9 (16%)” | “1 (2%)” | “6 (38%)” | “4 (25%)” | “0” |
| Nausea | “41 (73%)” | “2 (4%)” | “0” | “11 (69%)” | “1 (6%)” | “0” |
| Fatigue | “30 (54%)” | “3 (5%)” | “0” | “9 (50%)” | “0” | “0” |
| Diarrhea | “24 (43%)” | “2 (4%)” | “0” | “4 (25%)” | “0” | “0” |
| Vomiting | “21 (38%)” | “1 (2%)” | “0” | “4 (25%)” | “0” | “0” |
| Electrocardiogram QT prolonged | “16 (29%)” | “4 (5%)” | “0” | “4 (25%)” | “1 (6%)” | “0” |
| AST increased | “15 (27%)” | “2 (4%)” | “0” | “3 (19%)” | “0” | “0” |
Adverse events including neutropenia: combination with palbociclib
Bradycardia and photopsia: phase 1/2 monotherapy
“TEAEs of oral SERDs observed in less than 10% of patients treated at the RP2D of palazestrant included bradycardia (9%) and photopsia (5%); all bradycardia and photopsia events were grade 1, and there were no dose modifications, interruptions, or discontinuations due to these events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, unlike with other SERDs that have reported rates of up to 45% for bradycardia and 56% for photopsia, the incidence of bradycardia and photopsia was lower with palazestrant (9% and 5%, respectively) [25, 28, 29].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
QTc interval: monotherapy and combination with ribociclib
“There were no clinically significant changes in the QT interval corrected by the Fridericia formula (QTcF) in any patients treated with palazestrant, and no QTcF values exceeded 500 ms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gastrointestinal toxicity: nausea, vomiting, and diarrhea
“The most frequently reported TRAEs were gastrointestinal events and fatigue, which have also been commonly reported with SERDs and selective ER covalent antagonists (SERCAs) [24–27].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients treated with the RP2D of palazestrant, the rate of treatment-related diarrhea of any grade was 13%, and there were no grade ≥ 3 events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic laboratory abnormalities
“In this study, DLTs included any treatment-related fatal adverse event (AE); grade ≥ 3 nonhematologic toxicity (including nausea, vomiting, diarrhea not resolving within 3 days with optimal treatment, and fatigue lasting > 7 days); grade 3 neutropenia (with fever and/or infection); grade 3 thrombocytopenia (with bleeding); grade ≥ 4 hematologic toxicity; grade ≥ 2 AEs that resulted in treatment discontinuation or interruption for at least a week (during cycle 1) or a delay of cycle 2 for at least a week; and protocol-defined elevations of aspartate aminotransferase (AST) or alanine aminotransferase (ALT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seven patients discontinued palazestrant due to AEs, of which 5 were assessed as related to palazestrant: grade 4 febrile neutropenia with no evidence of infection, grade 4 neutropenia, grade 3 nausea, grade 3 international normalized ratio increase, and grade 2 fatigue.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| TEAE, 120 mg (n = 83) | Grade 1 | Grade 2 | Grade 3 | Grade 4 | All (%) |
|---|---|---|---|---|---|
| AST increased | “10” | “2” | “1” | “0” | “13 (16%)” |
Discontinuations due to adverse events: phase 1/2 monotherapy
“Reasons for treatment discontinuation included radiographic disease progression (n = 78 [67.2%]), clinical disease progression (i.e., without disease progression per RECIST v1.1) (n = 11 [9.5%]), AEs (n = 7 [6.0%]), withdrawal of consent (n = 4 [3.4%]), and other reasons (n = 2 [1.7%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety assessments and independent data monitoring in OPERA-01
“Safety and tolerability (AEs, SAEs, dose modifications, clinical laboratory parameters, ECGs, performance status, and vital sign measurements)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse event (AE) severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An independent data monitoring committee (IDMC), comprising medical and statistical representatives not involved in the trial, is monitoring the safety, efficacy, and conduct of the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Class context: dyslipidemia and embryo-fetal toxicity with elacestrant
Class context: QTc prolongation and bradycardia with camizestrant
Class context: QTc prolongation with vepdegestrant
Special populations
Age range studied and older adults
| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
|---|---|---|---|
| Age, years; median (range) | “59.5 (30–81)”View highlighted excerpt for this quote | “61.0 (32–85)”View highlighted excerpt for this quote | “61.0 (30–85)”View highlighted excerpt for this quote |
| Characteristic | 90 mg + ribociclib (n = 16) | 120 mg + ribociclib (n = 56) | Total (N = 72) |
|---|---|---|---|
| Median age, yrs (range) | “60 (25-76)” | “61 (28-85)” | “61 (25-85)” |
Men: eligibility and enrollment
“Patients eligible for phase 1a of the study included adult men or women of any menopausal status with inoperable histologically or cytologically confirmed ER+/HER2− advanced or metastatic breast cancer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Male and female participants aged 18 years or older are eligible for enrollment in the OPERA-01 study if they have a confirmed diagnosis of inoperable locally advanced or metastatic ER+, HER2– breast cancer that is not amenable to curative treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
|---|---|---|---|
| Female, n (%) | “30 (100)”View highlighted excerpt for this quote | “86 (100)”View highlighted excerpt for this quote | “116 (100)”View highlighted excerpt for this quote |
Premenopausal women: ovarian suppression and enrollment
“Pre- or perimenopausal women were required to use luteinizing hormone–releasing hormone agonists for the duration of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
|---|---|---|---|
| Childbearing potential: yes, n (%) | “0”View highlighted excerpt for this quote | “7 (8.1)”View highlighted excerpt for this quote | “7 (6.0)”View highlighted excerpt for this quote |
“The reproductive status of female participants has been reported as having a childbearing potential (yes vs no)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Characteristic | 90 mg + ribociclib (n = 16) | 120 mg + ribociclib (n = 56) | Total (N = 72) |
|---|---|---|---|
| Premenopausal, n (%) | “4 (25%)” | “8 (14%)” | “12 (17%)” |
Pregnancy, lactation, and contraception requirements in clinical trials
Nonclinical reproductive and developmental toxicology
No evidence found.
Class context: embryo-fetal toxicity with imlunestrant
Renal impairment: trial exclusion criteria
Hepatic and renal impairment: dedicated pharmacokinetic studies
No evidence found.
Central nervous system metastases: phase 2 cohort and exclusion from OPERA-01
“Phase 2 further explored the safety and antitumor activity of palazestrant at the RP2D in patients with measurable disease (primary cohort), nonmeasurable evaluable disease (exploratory cohort), and CNS metastases (exploratory cohort, not included in this report).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Palazestrant has demonstrated activity in both ESR1-wild type (ESR1-wt) and ESR1-mutated (ESR1-mut) preclinical models as well as central nervous system (CNS) penetration and demonstrated antitumor activity in brain metastasis models.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CNS metastases, carcinomatous meningitis, leptomeningeal disease, or spinal cord compression that requires immediate CNS-directed treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Race of participants in the phase 1/2 monotherapy trial
Drug/Drug, drug/disease interactions
Effects of other drugs on Palazestrant
Strong CYP3A4 inhibitors and inducers in the phase 1/2 study
Medications with a known risk of QT prolongation
“Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proton pump inhibitors and antiemetics
“In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CYP3A4 metabolism and sensitivity to inhibition
Effect of ribociclib on palazestrant trough concentrations
Dose-normalized palazestrant trough concentrations with and without ribociclib
| Study | Dose-normalized steady-state trough, geometric mean (geometric SD); n | 90% confidence interval |
|---|---|---|
| OP-1250-001, single agent | “2.49 (48%); 172” | “[2.35, 2.64]” |
| OP-1250-003, combination with ribociclib | “3.35 (61%); 25” | “[2.77, 4.06]” |
Ribociclib and palazestrant exposure at the September 2024 data cutoff
Ribociclib and palazestrant exposure at the July 2025 data cutoff
Effect of palbociclib on palazestrant exposure
Effects of Palazestrant on other drugs
In vitro CYP3A4 and transporter inhibition
“Low risk of transporter inhibition by compound 21 was determined by in vitro P-gp and BCRP assays (IC50 = 4 and >5 μM, respectively). No inhibitory activity was observed for the CYP 3A4 isoform (IC50 > 10 μM).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ribociclib exposure with palazestrant 30 to 120 mg
Steady-state ribociclib parameters with and without palazestrant
| Steady-state parameter | Ribociclib single agent | Ribociclib in combination with palazestrant |
|---|---|---|
| AUC0-24 ([h*ng/mL]/mg), GeoMean (GeoCV); N | “23,800 (66%); 54” | “25,400 (78%); 8” |
| Cmax (ng/mL/mg), GeoMean (GeoCV); N | “1,820 (62%); 57” | “1,860 (66%); 8” |
| Tmax (h), median (min–max); N | “2.4 (0.68–7.8); 57” | “4.0 (1.0–6.0); 8” |
Ribociclib exposure at the September 2024 data cutoff
Ribociclib exposure at the July 2025 data cutoff
Palbociclib exposure with palazestrant
Company summary of the palbociclib interaction data
Dosing and administration
Dosage
Recommended phase 2 dose of 120 mg
“Based on the tolerable safety profile, favorable PK, and encouraging antitumor activity shown in the phase 1 portion of the study, the 120 mg/day dose was chosen as the RP2D.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limited data were available for patients treated with 90 mg palazestrant, as only 6 patients were enrolled during dose escalation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose reductions during dose escalation
Dose modification for neutropenia in the monotherapy study
“these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors, and following dose reductions, 3 patients were able to continue palazestrant with no further recurrences of neutropenia” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reduced dose levels after grade 4 neutropenia
Blood count monitoring and dose modification in ongoing studies
“All ongoing studies with palazestrant include proactive monitoring of blood counts that is more frequent during first 6–8 weeks after initiation of palazestrant, with the possibility for dose reduction or interruption following the detection of grade 3 or 4 neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
OPERA-01 dose selection design
“In Part 1, the dose-selection portion of the study, eligible participants were randomized 1:1:1 to receive oral palazestrant at a dose of 90 mg or 120 mg once daily (QD) or investigator’s choice of SOC ET” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Independent Data Monitoring Committee recommended a 90-mg palazestrant QD dose based on the available safety, efficacy, patient-reported outcomes, and pharmacokinetic data from participants treated in Part 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Part 2, participants receive once-daily palazestrant (90 mg QD) or SOC ET as described in Part 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose selected with the FDA for the phase 3 trials
Phase 3 dose as monotherapy and with ribociclib
OPERA-02 registry dosing
Dosing with palbociclib
Dose reductions with ribociclib
Administration
Route, frequency, and cycle length in the phase 1/2 study
Tablet formulation and administration with food in ongoing studies
Cycle length and treatment duration in OPERA-01
“All treatments are administered in 28-day cycles and continue until confirmed radiographic disease progression, intolerable toxicity, continuous dose-interruption >28 days, investigator or participant decision, or initiation of a non-protocol anti-cancer therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Once-daily schedule in the OPERA-01 registry record
Access and distribution
Commercial launch preparation underway (November 2026)
Commercial planning, supply and distribution, and field force
Manufacturing by contract manufacturing organizations, including commercial supply
Specialty pharmacy or distribution network
No evidence found.
Co-prescribed/Concomitant therapies
Gonadotropin-releasing hormone or LHRH agonists for premenopausal women and men
“Pre- or perimenopausal women were required to use luteinizing hormone–releasing hormone agonists for the duration of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fulvestrant or the AIs letrozole, anastrozole, or exemestane (with gonadal suppression in pre- and perimenopausal women or men) are included as the physician’s choice of SOC ET monotherapy for the control arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Combination partners under study: CDK4/6, CDK4, PI3Kα, and mTOR inhibitors
Ribociclib: dosing and pharmacokinetic compatibility
Palbociclib: dosing and pharmacokinetic compatibility
Antiemetics and proton pump inhibitors
“In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue [26].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Colony-stimulating factors for neutropenia
Medications not permitted: QT-prolonging drugs and strong CYP3A4 inhibitors or inducers
“Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“any condition requiring medications not permitted during the study (e.g., strong CYP3 A4 inhibitors/inducers)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Washout of prior anticancer therapies
“Prior CDK4/6 inhibitors, fulvestrant, alpelisib, everolimus, or poly-adenosine diphosphate ribose polymerase inhibitors were allowed if discontinued at least 2 weeks prior to the first dose of palazestrant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bone-modifying agents
No evidence found.
Effect of Palazestrant on quality measures
MIPS Quality ID 453: systemic cancer-directed therapy in the last 14 days of life
MIPS Quality ID 457: hospice admission for less than 3 days before death
MIPS Quality ID 143: pain intensity quantified
MIPS Quality ID 144: plan of care for pain
Enhancing Oncology Model: episodes with hormonal therapy only and quality strategy
Product-specific effect on quality measures
No evidence found.
Product comparison
Palazestrant: class, dosing, and OPERA-01 population
“Palazestrant is a next-generation, orally bioavailable complete estrogen receptor antagonist (CERAN) and SERD with potent activity targeting the ER” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Palazestrant promotes ER degradation at levels similar to that of fulvestrant and greater than that of elacestrant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Part 2, participants are randomized at a 1:1 ratio to receive once‑daily oral palazestrant (90 mg QD) or the investigator’s choice of SOC ET.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OPERA-01 (NCT06016738) is a phase III study designed to evaluate the safety and efficacy of palazestrant monotherapy compared to SOC ET in patients with ER+, HER2– locally advanced or metastatic breast cancer, regardless of ESR1 mutation status, whose disease advanced following treatment with at least one ET in combination with a CDK4/6i.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“trials investigating the efficacy of the PROteolysis Targeting Chimera ER degrader (PROTAC), vepdegestrant, and the SERD, imlunestrant, showed progression-free survival (PFS) benefits specific to patients harboring ESR1 mutations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Palazestrant: phase 1/2 formulation, efficacy, and comparison with other estrogen receptor-targeting agents
“All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles. In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 120 mg/day, the median progression-free survival was 4.8 months (95% CI, 3.5–7.1) overall and 5.6 months (95% CI, 4.8–NE) among patients with cancers with ESR1 mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, unlike with other SERDs that have reported rates of up to 45% for bradycardia and 56% for photopsia, the incidence of bradycardia and photopsia was lower with palazestrant (9% and 5%, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CERAN/SERD mechanism of action of palazestrant is shared by fulvestrant, camizestrant and imlunestrant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Elacestrant, which is a selective ER modulator (SERM) and SERD, does not completely shut down ER signaling due to being an partial agonist and was also more active in cancers harboring ESR1 mutations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“although a direct comparison has not been performed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Palazestrant: competing estrogen receptor-targeting products named by the sponsor
Elacestrant (Orserdu): indication, regimen, EMERALD efficacy, and warnings
Elacestrant: EMERALD progression-free survival in all patients and in patients with ESR1 mutation
“PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; P = .002) and patients with ESR1 mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; P = .0005).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Elacestrant (Orserdu): wholesale acquisition cost at launch
| Strength | NDC | Pack size | WAC (as of date of commercial availability) | Date of commercial availability |
|---|---|---|---|---|
| 86 mg | “72187010103” | “30 tablets” | “$7,123.00” | “2/3/2023” |
| 345 mg | “72187010203” | “30 tablets” | “$21,369.00” | “2/3/2023” |
Imlunestrant (Inluriyo): indications, regimen, EMBER-3 efficacy, and warnings
Imlunestrant (Inluriyo): wholesale acquisition cost
| Strength and dosage form | NDC | Pack size | Wholesale acquisition cost |
|---|---|---|---|
| 200 mg tablet | “0002-1717-28” | “28” | “$11,250.00” |
| 200 mg tablet | “0002-1717-56” | “56” | “$22,500.00” |
Vepdegestrant (Veppanu): indication, regimen, VERITAC-2 efficacy, and warnings
Camizestrant (Etcamah): indication, regimen, SERENA-6 efficacy, and warnings
Fulvestrant (Faslodex): indications, regimen, CONFIRM efficacy, and warnings
Capivasertib (Truqap): indication, regimen, CAPItello-291 efficacy, and warnings
Capivasertib: CAPItello-291 progression-free survival in the overall and AKT pathway-altered populations
“In the overall population, the median progression-free survival was 7.2 months in the capivasertib–fulvestrant group, as compared with 3.6 months in the placebo–fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.51 to 0.71; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the AKT pathway–altered population, the median progression-free survival was 7.3 months in the capivasertib–fulvestrant group, as compared with 3.1 months in the placebo–fulvestrant group (hazard ratio, 0.50; 95% CI, 0.38 to 0.65; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events leading to discontinuation were reported in 13.0% of the patients receiving capivasertib and in 2.3% of those receiving placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Capivasertib (Truqap): wholesale acquisition cost of blister packs
| Product | NDC | Order quantity | WAC price |
|---|---|---|---|
| 160 mg tablets, 4 x 16 blister pack | “00310-9500-02” | “1 Blister Package (4x16)” | “$22,922.00” |
| 200 mg tablets, 4 x 16 blister pack | “00310-9501-02” | “1 Blister Package (4x16)” | “$22,922.00” |
Gedatolisib (Revtorpyk): indication, regimen, VIKTORIA-1 efficacy, and warnings
Gedatolisib: VIKTORIA-1 progression-free survival hazard ratios and discontinuation
“The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Study treatment discontinuation because of TRAEs was reported in 2.3% (triplet) and 3.1% (doublet) of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gedatolisib (Revtorpyk): wholesale acquisition cost
Place of product in therapy
Disease description
Definition and etiology
Hormone receptor-positive and HER2-positive tumor definitions
Estrogen receptor-positive threshold: ASCO/CAP guideline
“Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HER2 status: ASCO/CAP guideline
“The 2018 ASCO-CAP recommendations for HER2 testing are affirmed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This update acknowledges a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified but is immunohistochemistry (IHC) 1+ or 2+ without amplification by in situ hybridization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intrinsic subtypes and their hormone receptor surrogates
Advanced breast cancer: international consensus definition
“In the ABC guidelines, advanced breast cancer is defined as comprising both inoperable locally advanced breast cancer (LABC) and metastatic breast cancer (MBC), which includes both distant recurrent disease and stage IV at diagnosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Advanced/metastatic breast cancer is still an incurable disease for the vast majority of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distant stage and stage IV classification
De novo and recurrent metastatic disease
“Distant metastatic breast cancer (MBC), including metastases found at diagnosis (de novo) and those occurring later (recurrence), represents the most severe form of the disease, when resource utilization is most intensive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Previously treated disease: endocrine resistance definitions
“Primary endocrine resistance is defined as relapse while on the first two years of adjuvant endocrine therapy for early breast cancer, or progressive disease within the first six months of first line endocrine therapy-based treatment for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary or acquired endocrine resistance encompasses all remaining clinical situations of endocrine resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The first subgroup, early acquired endocrine resistance , includes relapse while receiving endocrine therapy but after the first two years, relapse within one year of completing adjuvant endocrine therapy, or progressive disease occurring after at least six months, but less than twelve months, of first line endocrine therapy-based treatment for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The second subgroup, late acquired endocrine resistance , is defined as relapse more than twelve months after completing adjuvant endocrine therapy, or progressive disease after at least twelve months of first line endocrine therapy-based treatment for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: U.S. summary
Risk factors: hormone receptor-positive disease and reproductive history
Risk factors: NCI health professional summary
Epidemiology
Incidence of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer
U.S. estimated new cases and deaths, 2026
U.S. incidence rate of female breast cancer per 100,000
U.S. incidence rate of HR-positive/HER2-negative breast cancer per 100,000
U.S. share of cases that are HR-positive/HER2-negative, by race and ethnicity
U.S. incidence trends, all stages and distant stage
U.S. annual new metastatic diagnoses, de novo and recurrent
U.S. new metastatic female breast cancer cases, 2018 estimate and 2025 projection
| Measure | Breast (female) |
|---|---|
| Number of new metastatic cancer cases, de novo (observed), 2018 | “15 800”View highlighted excerpt for this quote |
| Number of new metastatic cancer cases, de novo and recurrence (estimated), 2018 | “46 666”View highlighted excerpt for this quote |
| Projected number of new metastatic (de novo and recurrence) cancer cases, 2025 | “52 126”View highlighted excerpt for this quote |
Risk of distant recurrence after 5 years of adjuvant endocrine therapy for ER-positive disease
“Breast-cancer recurrences occurred at a steady rate throughout the study period from 5 to 20 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the patients with stage T1 disease, the risk of distant recurrence was 13% with no nodal involvement (T1N0), 20% with one to three nodes involved (T1N1–3), and 34% with four to nine nodes involved (T1N4–9); among those with stage T2 disease, the risks were 19% with T2N0, 26% with T2N1–3, and 41% with T2N4–9.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Worldwide incidence, GLOBOCAN 2024
“With an estimated 2.4 million new cases and 694,000 deaths, female breast cancer is the second most commonly diagnosed cancer and the fourth leading cause of cancer death in 2024, accounting for 11.8% of all cases and 7.1% of all deaths” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence rates are elevated in Australia/New Zealand, Northern America, and Northern Europe (90–102 per 100,000) and are approximately three times higher than those in Eastern Africa, South Central Asia, and Middle Africa (29–33 per 100,000;” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Worldwide incidence by human development index
Prevalence of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer
U.S. women living with breast cancer, all stages
U.S. women living with metastatic breast cancer, 2013 and 2017
“In 2013, the last year with observed data, we estimate a prevalence of MBC of 138,622 of which 38,897 (28%) are survivors who were initially diagnosed with de novo stage IV disease and 99,725 (72%) survivors initially diagnosed with stage I–III BC who later progressed to MBC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We project that by 1/1/2017 there will be 154,794 women living with MBC in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. women living with metastatic breast cancer: duration since metastatic diagnosis
U.S. individuals living with metastatic female breast cancer, 2018 estimate and 2025 projection
| Measure | Breast (female) |
|---|---|
| Number living with metastatic disease on January 1, 2018, de novo (observed) | “54 117”View highlighted excerpt for this quote |
| Number living with metastatic disease on January 1, 2018, de novo and recurrence (estimated) | “140 230”View highlighted excerpt for this quote |
| Projected number living with metastatic disease (de novo and recurrence) on January 1, 2025 | “169 347”View highlighted excerpt for this quote |
“Almost 30% of individuals diagnosed with metastatic melanoma and one-fifth of individuals diagnosed with metastatic colorectal or metastatic breast cancer are estimated to have been living with metastatic disease for 10 or more years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The number of individuals living with metastatic cancer is projected to increase from 2019 to 2025 for breast, bladder, colorectal, and prostate cancer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. share of women living with metastatic disease first diagnosed at stage I to III
U.S. prevalence of previously treated ER-positive HER2-negative advanced disease
No evidence found.
Worldwide 5-year prevalence of breast cancer by continent, GLOBOCAN 2024
| Continent | 5-year prevalent cases | Percent |
|---|---|---|
| Asia | “3 291 849” | “40.3%” |
| Europe | “2 208 013” | “27.1%” |
| Northern America | “1 373 135” | “16.8%” |
| Latin America and the Caribbean | “670 478” | “8.2%” |
| Africa | “491 878” | “6.0%” |
| Oceania | “126 982” | “1.6%” |
Natural history, survival, and mortality
U.S. breast cancer deaths, 2026
Contribution of metastatic disease treatment to the decline in U.S. mortality
U.S. 5-year relative survival for HR-positive/HER2-negative disease by stage, SEER 21, 2016 to 2022
Goals of treatment for metastatic disease
U.S. survival after de novo metastatic diagnosis over time
“Median relative survival time increased from 22.3 to 38.7 months and from 19.1 to 29.7 months for women diagnosed between ages 15–49 and 50–64, respectively, during 1992–1994 versus 2005–2012.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite a poor prognosis there is a small but meaningful percent of these cases who survive 10-years or more; more than 11% of women diagnosed between 2000–2004 under the age of 64 years survived 10 years or more.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. breast cancer-specific survival in de novo HR-positive/HER2-negative metastatic disease before and after CDK4/6 inhibitors
“In the unadjusted analysis of patients with HR+/HER2− mBC, BCSS was significantly longer among patients in the post-2015 group versus the pre-2015 group (median BCSS: 39 [95% CI 38–42] vs 35 [95% CI 33–37] months; hazard ratio [HR] = 0.896, 95% CI 0.849–0.946; p < 0.001;” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 48-month BCSS rate was 44.5% for the post-2015 group and 38.5% for the pre-2015 group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. real-world overall survival with first-line CDK4/6 inhibitor plus aromatase inhibitor
“Of 9146 eligible patients, 6831, 1279, and 1036 received palbociclib plus AI, ribociclib plus AI, or abemaciclib plus AI, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After sIPTW, median OS was 54.6 months (95% CI 52.6-56.4 months) in the palbociclib group, 59.0 months (95% CI 50.9-66.1 months) in the ribociclib group, and 64.5 months (95% CI 55.4 months-not estimable) in the abemaciclib group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. real-world outcomes of second-line therapy after progression on a first-line CDK4/6 inhibitor
“A total of 839 patients received a documented second-line therapy after progression on first-line CDK4/6i treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median unadjusted rwPFS and OS for those who received a CDK4/6i in the second-line setting were 8.25 months and 35.7 months, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median rwPFS for those patients who received chemotherapy, fulvestrant monotherapy, or everolimus were 3.71, 3.25, and 3.32 months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review: real-world progression-free survival after a first-line CDK4/6 inhibitor
“Twenty records (9 full-text articles and 11 conference abstracts) encompassing 18 unique studies met the eligibility criteria and reported outcomes for second-line (2 L) treatments after 1 L CDK4/6i; no studies reported disaggregated outcomes in the third-line setting or beyond.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most assessed outcome was median rwPFS; the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Second- and third-line real-world progression-free survival by intrinsic subtype, Spain
“Median rwPFS-2L was 7.2 months in luminal IS vs. 6.1 in non-luminal (HR 1.40; 95% CI 0.86–2.30); the Basal-like (BL) subtype correlated with significantly shorter rwPFS-2L (HR 3.82; 95% CI 1.07–13.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In rwPFS-3L, similar trends were seen (6.4 vs. 3.3 months; HR 1.74; 95% CI 0.98–3.08), with BL showing the poorest outcomes (HR 5.63; 95% CI 1.17–27.02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Acquired ESR1 mutations along the treatment course
“Approximately 20–40% of patients who have received aromatase inhibition (AI) for MBC have ESR1 mutations, with prevalence varying by sites of metastatic disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, ESR1 mutations in HR-positive breast cancer occur almost exclusively after AI in the metastatic setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, ESR1 mutations usually occur with several concurrent genomic alterations, and together, these confer a globally worse prognosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients receiving 1st-line aromatase inhibitor + CDK4/6 inhibitor (n = 573) with ESR1mut had less favorable rwPFS and rwOS versus ESR1 wild-type; no differences were observed for fulvestrant + CDK4/6 inhibitor (n = 348).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESR1 mutation and overall survival after prior aromatase inhibitor, BOLERO-2
“Of 541 evaluable patients, 156 (28.8%) had ESR1 mutation D538G (21.1%) and/or Y537S (13.3%), and 30 had both.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These mutations were associated with shorter overall survival (wild-type, 32.1 months [95% CI, 28.09-36.40 months]; D538G, 25.99 months [95% CI, 19.19-32.36 months]; Y537S, 19.98 months [13.01-29.31 months]; both mutations, 15.15 months [95% CI, 10.87-27.43 months]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Worldwide population-level survival trends in de novo and recurrent metastatic disease
“For dnMBC, 13 of 14 studies reported improved OS or BCSS since 1995. In 2005–2009, the median OS was 26 months (range 24–30), a median gain of 6 months since 1995–1999 (range 0–9, 4 studies).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For rMBC, one study reported no change in survival between 1998 and 2006 and 2007–2013 (median OS 23 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Population-level improvements in OS for dnMBC have not been consistently observed in rMBC cohorts nor older women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Worldwide mortality, GLOBOCAN 2024
“Among women, breast cancer is the most common cancer for both incidence and mortality worldwide, ranking first for incidence in 164 countries” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mortality rates range from 20 to 25 per 100,000 in Melanesia, Micronesia/Polynesia, and Western Africa and from six to 10 per 100,000 in Eastern Asia and Central America.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Worldwide survival gains in ER-positive/HER2-negative advanced disease
“While important progress has been made, including the doubling of the median overall survival for two of the three ABC subtypes, the disease remains incurable for the vast majority of patients and inequities in access to the best diagnostic and therapeutic options and to high quality, multidisciplinary, evidence-based care have increased in the last decade.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Estrogen receptor expression and dependence on estrogen receptor signaling
“Upon activation by oestrogen, ER executes a transcriptional programme that drives proliferation and expansion of the mammary epithelia during puberty” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“~70–80% of tumours that emerge from the mammary gland express ER and harbour some dependence on ER signalling for proliferation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although most ER+ tumours initially appear sensitive to anti-oestrogen agents, resistance can develop over time, characterized by clinical relapse, which typically involves the emergence of genetic and epigenetic alterations that allow for reactivation of ER signalling” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ligand-dependent estrogen receptor activation
Activation function domains AF-1 and AF-2
“ER consists of two transcriptional activation domains, the N-terminal ligand-independent activation function (AF)-1 and the C-terminal ligand-dependent AF-2 domains, a ligand-binding domain (LBD) also residing in the C-terminal region, and the DNA-binding and hinge domains, positioned in the core of the protein.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AF-1 activity and incomplete antagonism by selective estrogen receptor modulators
“SERMs still allow for the engagement of ER with chromatin and therefore do not inhibit transcription driven by the N-terminal ER activation function-1 (AF1) domain” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As AF1 activity is sensitive to various cellular inputs, the impact of SERMs on ER transcriptional output depends on the tissue environment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Selective ER degraders inhibit both LBD and AF1 domains by preventing recruitment of co-activators, immobilizing and destabilizing ER, leading to degradation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESR1 ligand-binding domain mutations in the AF-2 region
“All ESR1 mutations were located within the LBD/activation function-2 (AF-2) domain of the receptor and the majority occurred specifically at amino acids 537 and 538 of helix 12” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with this model, mutant receptors drive ER-dependent transcription and proliferation in the absence of hormone and reduce the efficacy of ER antagonists.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Constitutive activity and reduced drug binding of mutant estrogen receptor
“Whereas wild-type ESR1 (ESR1-WT) is bound by estrogen ligand to enable coactivator recruitment, LBD-mutated ESR1 (ESR1-MUT) is constitutively active and thus unaffected by AI depletion of estrogen” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For tamoxifen, ESR1-MUT has up to 30-fold decreased binding affinity (varying by specific mutation) and requires higher doses to inhibit transactivation function and cell proliferation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For fulvestrant, ESR1-MUT has up to 40-fold decreased binding affinity and, like tamoxifen, requires an increased dose by an order of magnitude to inhibit transactivation function and cell expansion in culture and xenograft models” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESR1 mutations acquired under aromatase inhibitor therapy for metastatic disease
“ESR1 mutations were found exclusively in patients with estrogen receptor positive breast cancer previously exposed to AI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESR1 mutation prevalence differed markedly between patients that were first exposed to AI during the adjuvant and metastatic settings (5.8% (3/52) vs 36.4% (16/44) respectively, p=0.0002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESR1 mutations are rarely acquired during adjuvant AI therapy, but are commonly selected by therapy for metastatic disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of ESR1 mutations by prior endocrine therapy setting
“The prevalence of ESR1 mutations in patients depends on prior duration and setting of endocrine therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 20–40% of patients who have received aromatase inhibition (AI) for MBC have ESR1 mutations, with prevalence varying by sites of metastatic disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, ESR1 mutations in HR-positive breast cancer occur almost exclusively after AI in the metastatic setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of ESR1 mutations in plasma after aromatase inhibitor exposure in BOLERO-2
Prevalence of ESR1 mutations by line of therapy in real-world genomic testing
“ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the prevalence of ESR1mut in TBx collected within 60 days before or after the initiation of 1st, 2nd, and 3rd lines of therapy was 8.1% (n = 175/2,154), 27.1% (n = 73/269), and 33.3% (n = 72/216), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of ESR1 mutations before and after endocrine therapy
ESR1 mutation as one of several endocrine resistance mechanisms
“About 50% of endocrine resistance cases are associated with an ESR1 mutation; other mechanisms, increasingly uncovered, include alterations in the PI3K-AKT-mTORC1, RAS-MAPK, and CDK4/6-RB-E2F pathways, and ESR1 loss, amplification, and translocation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESR1 fusions are rare but exhibit complete resistance to treatments targeting the LBD of ESR1 such as selective estrogen receptor modulators (SERMs) and degraders (SERDs), as these fusions lack the LBD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ligand-independent estrogen receptor reactivation through growth factor signaling
“Instead, endocrine resistance is commonly driven by ligand-independent ER reactivation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upon adaptation and/or resistance to antiestrogens, growth factor-driven mitogenic and survival pathways (i.e., PI3K/mTOR, RAS/RAF/MEK/ERK) can drive reactivation of ER transcription in the absence of estradiol.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These resistant tumors are typically dependent upon both the aberrantly activated survival pathway and ER, and in most cases combined inhibition of both pathways is more effective” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PI3K, AKT, and PTEN pathway alterations
“Components of the PI3K pathway (including PIK3CA, PTEN, and AKT1) are frequently mutated in ER+ breast cancers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Aberrant activation of the PI3K pathway promotes acquired resistance to estrogen depletion in preclinical models” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AKT1 and PTEN mutations are more frequent in advanced/metastatic ER+ breast cancers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of PI3K, AKT, and PTEN alterations by line of therapy
“1002 (17.3%) TBx and 503 (30.1%) LBx had an ESR1mut detected; 2,442 (42.2%) TBx and 564 (33.8%) LBx had a PIK3CAmut detected; 289 (5%) TBx and 70 (4.2%) LBx had an AKT1mut detected; and 602 (10.4%) TBx and 41 (2.5%) LBx had a PTEN alteration (mut or loss) detected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We observed that the prevalence of an alteration in the PI3K/AKT pathway in TBx collected in 1st, 2nd, and 3rd lines of therapy was 55.1% (n = 1,186/2,154), 48.3% (n = 130/269), and 54.6% (n = 118/216), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with TBx in 1st (n = 2154), 2nd (n = 269), and 3rd (n = 216) lines, both ESR1mut and a PI3K/AKT pathway GA were detected in 4.4% (95), 8.2% (22), and 17.1% (37), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resistance to CDK4/6 inhibitors
“Some of the somatic alterations described above have also been shown to promote resistance to CDK4/6i, including FGFR1 amplification, PTEN alterations, and ERBB2 mutations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, RB1 and FAT1 alterations appear to be exclusively associated with resistance to CDK4/6 inhibitors and less to antiestrogens alone” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Acquired hotspot mutations in PIK3CA have been reported following progression on either fulvestrant alone or in combination with CDK4/6 inhibitors (CDK4/6i)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estrogen receptor-independent growth and loss of estrogen receptor expression
“Loss of ER expression occurs in a minority (~10%) of endocrine-resistant breast cancers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition to ER, RTKs activate other transcription factors that promote ER-independent survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Indeed, Razavi et al. reported that 60% of endocrine-resistant MBC lacked known somatic drivers of resistance” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estrogen receptor-dependent and estrogen receptor-independent routes of resistance
“Still, these may be thought of as either (1) reactivating ER signalling despite drug administration or (2) bypassing ER to drive another oncogenic programme” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interestingly, resistance mechanisms relating to active ER signalling are more typically observed in tumours that manifest with a period of apparent sensitivity followed by resistance, that is, resistance that is acquired under the pressure of therapy, whereas ER-independent mechanisms often appear in tumours that are intrinsically resistant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pink and red: other cancers lose dependency on ER altogether.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Estrogen receptor testing by immunohistochemistry
“The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HER2 testing and the distinction between immunohistochemistry 0 and 1+
“The 2018 ASCO-CAP recommendations for HER2 testing are affirmed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This update acknowledges a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified but is immunohistochemistry (IHC) 1+ or 2+ without amplification by in situ hybridization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, while it is premature to create new result categories of HER2 expression (eg, HER2-Low, HER2-Ultra-Low), best practices to distinguish IHC 0 from 1+ are now clinically relevant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Biopsy of metastatic disease and reassessment of receptor status
Biopsy guidance for bone-only metastatic presentation
“All patients with newly diagnosed lesions should have a biopsy, if clinically feasible, to confirm the presence of breast cancer and to assess the subtype of the recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Biological markers (especially ER and HER2) should be reassessed at least once in the metastatic setting, even in case of a bone-only metastatic presentation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If a bone lesion is the biopsy site, it is preferable to biopsy a mixed lytic and sclerotic lesion rather than a pure sclerotic area to increase the chance of retrieving adequate high-quality cells to assess.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ASCO recommendation for ESR1 testing at recurrence or progression
ESMO recommendation for ESR1 and PI3K pathway testing
ABC8 recommendation for plasma ctDNA testing for ESR1 at progression
“The recommendation to test blood ctDNA at disease progression, provided that a targeted treatment is available, is consistent with the biology of ESR1 mutations as acquired mechanisms of endocrine resistance, their enrichment after aromatase inhibitor exposure, and the fact that plasma may better capture their polyclonal emergence than a single tissue biopsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The recommendation to consider tissue testing when plasma is negative, and to repeat testing under continued endocrine-based therapy if the result would influence treatment choice, is clinically sound” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We do not recommend ctDNA assessment for the demonstration of disease progression, while recognizing that ctDNA is an appropriate option to detect actionable genomic alterations for treatment selection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multigene panels on plasma or tissue
“now explicitly supporting the use of multigene assays performed on plasma ctDNA and/or tissue, not only to facilitate enrollment into clinical trials but also to identify clinically actionable alterations, particularly ESR1 mutations and alterations in the PIK3CA/AKT/PTEN pathway” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“in particular, plasma is preferred for ESR1 testing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Timing of tissue and liquid biopsy along the treatment course
“Our study suggests obtaining TBx for CGP at time of de novo/recurrent diagnosis, followed by LBx for detecting acquired GA in 2nd + lines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reflex TBx should be considered when ctDNA TF < 1%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Detection technologies and polyclonality of ESR1 mutations
“Sample sources include solid tissue biopsy, CTCs, and cell-free DNA (cfDNA); detection assays include next-generation sequencing (NGS) and droplet digital PCR (ddPCR), with ddPCR the most sensitive” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, subclonality, polyclonality, and distinct effects of different ESR1 mutations demonstrate the utility inherent in liquid biopsy as compared to solid tissue sampling in characterizing the tumor ecosystem.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PIK3CA testing in plasma with tissue reflex
“Candidates for a regimen with a phosphatidylinositol 3-kinase inhibitor and hormonal therapy should undergo testing for PIK3CA mutations using next-generation sequencing of tumor tissue or circulating tumor DNA (ctDNA) in plasma to determine eligibility for alpelisib plus fulvestrant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If no mutation is found in ctDNA, testing in tumor tissue, if available, should be used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Companion diagnostic: Guardant360 CDx for ESR1 mutations
Imaging for baseline staging
Brain imaging
Response evaluation during treatment
Clinical presentation - signs and symptoms
Asymptomatic presentation
Asymptomatic patients in a real-world HR-positive, HER2-negative cohort
Site-dependent signs and symptoms of metastatic breast cancer
“They may be related to the primary tumour (i.e., a palpable mass in the breast or axilla) or to the secondary site of disease: skeletal pain in bone metastases, respiratory symptoms in lung or pleural disease, abdominal pain in peritoneal involvement and neurological symptoms in brain lesions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bone metastases: pain and fractures
Bone metastases: chronic pain from expanding lesions and pathologic fracture
“Many symptoms depend on the site of metastasis, with bone being the most frequent, and commonly occur with fatigue, depression, insomnia, and pain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Bone metastases are a common cause of chronic pain, with pain resulting directly from expanding lesions, pathologic fracture, or damage to adjacent structures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bone metastases: bone pain as the most frequent physician-reported symptom
Bone metastases: frequency in advanced disease
Neurological symptoms: spinal cord compression
“Spinal cord compression occurs in 5%–20% of cancer patients at autopsy and is a medical emergency requiring prompt evaluation and treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients should be evaluated for impending cord compression if there are complaints of back pain because bone metastases are present in 95% of cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central nervous system metastases: headache, seizures, and dizziness
Central nervous system metastases: leptomeningeal disease
“Leptomeningeal disease (LMD) is an aggressive complication of ABC with tumor cells infiltrating the leptomeninges, subarachnoid space, and CSF” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LMD is confirmed by positive CSF cytology or can be considered as probable (typical neurological signs and symptoms plus typical neuroimaging findings) or possible (atypical clinical and typical neuroimaging findings)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pulmonary and hepatic metastases: dyspnea, jaundice, and abdominal swelling
Respiratory symptoms: shortness of breath by treatment class
Visceral crisis: organ dysfunction from rapid progression
“Visceral crisis is usually defined as severe organ dysfunction as assessed by signs, symptoms and laboratory studies, resulting from rapid progression of neoplastic disease and indicative of substantial visceral compromise that may serve as an indication for more aggressive therapeutic intervention” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ABC guidelines further clarified visceral crisis as defined in liver as rapidly increasing bilirubin >1.5x ULN in the absence of an obstruction, and in lung as rapidly increasing dyspnea at rest in the absence of pleural effusion” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visceral crisis: frequency at diagnosis of advanced disease
“Visceral crisis is a life-threatening clinical condition requiring urgent treatment and accounts for 10–15% of new advanced breast cancer diagnoses, mainly hormone receptor-positive/human epidermal growth factor 2 negative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Peritoneal metastases: abdominal pain, nausea, and ascites
“Peritoneal carcinomatosis is more common in patients with invasive lobular carcinoma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients may present with non-specific symptoms such as abdominal pain, decreased appetite, nausea, vomiting, weight loss, increased abdominal girth. Ascites is present in 50 % of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Constitutional symptoms: fatigue
“Fatigue is the most commonly reported symptom in cancer patients, with an estimated prevalence of 25%–99% during treatment and 20%–35% off treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Potential contributing factors include the tumor burden, pain, difficulty sleeping, anemia, poor nutrition, inactivity, and other comorbid conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Constitutional and psychological symptoms reported by patients with HR-positive, HER2-negative metastatic disease
“Of the 319 patients who completed the EORTC-QLQ-C30/BR23, the most frequently-reported issues were tiredness (85.6%, n = 273), worrying about future health (75.9%, n = 242), and general worry (75.9%, n = 242; Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By treatment class, pain was reported by 80.8% of those who received chemotherapy monotherapy (n = 42), compared with 51.1% of those who received other targeted therapies (n = 24) and 63.6% who received ET+CDK4/6i (n = 110).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychological symptoms: depression and sleep disturbance
“Common vegetative symptoms of depression (fatigue, loss of appetite, insomnia) may be difficult to differentiate from symptoms related to metastases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fatigue and depression are often associated with sleep problems, whereas pain and menopausal vasomotor symptoms may interfere with sleep quantity and quality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Skeletal-related events in patients with bone metastases
“BM is associated with accelerated bone resorption leading to increased morbidity due to a range of skeletal-related events (SREs) including bone pain (BP), pathological fracture (PF), spinal cord compression (SCC), tumor-induced hypercalcemia (TIH) and surgery or radiation therapy (RT) to bone” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies have demonstrated that at least one SRE occurs in nearly 50% of patients with bone metastases of breast cancer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In randomized trials in advanced breast cancer, one of the major SREs occurs on average every 3–6 months after the onset of BM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevention of skeletal-related events with bone-modifying agents
“Patients with breast cancer who have evidence of bone metastases should be treated with BMAs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The analgesic effects of BMAs are modest, and they should not be used alone for bone pain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ESMO recommendations on bone metastases and skeletal-related events
Visceral crisis: prognosis
“The diagnosis of visceral crisis in metastatic breast cancer is associated with poor prognosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sbitti et al. showed a median Overall Survival (mOS) of 4.7 weeks in a retrospective cohort of 35 patients with hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer and visceral crisis pre-treated with two hormonal therapy lines, of whom 77 % had liver metastases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, the type of organic involvement in patients with VC is an established prognostic factor, with hepatic involvement being more associated with worse mOS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central nervous system metastases: incidence by subtype and line of therapy
“Among 18 075 patients with MBC, 1102 (6.1%) had at least 1 brain metastasis at first-line therapy initiation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For the remaining 16 973 patients, cumulative incidence of brain metastases at 60 months was 10% in patients with hormone receptor-positive (HR+)/HER2- disease, 23% for HR+/HER2+ disease, 34% for HR-/HER2+ disease, and 22% for triple-negative breast cancer (TNBC).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Brain metastases incidence increases per line of therapy for every MBC subtype.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Central nervous system metastases: pooled incidence in HR-positive, HER2-negative disease
“Four studies including 14656 patients reported the incidence of brain metastases specifically in patients with HR+/HER2− MBC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled cumulative incidence of brain metastases among this subgroup was 0.15 (95% CI: 0.078–0.27), with a median follow-up of 33.0 months (IQR: 31.9–36.2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central nervous system metastases: detection by screening MRI and ABC8 position
“Data from a non-randomized, prospective screening study in patients with ABC reveal that approximately one-quarter of patients across all subtypes (HR+/HER2-negative, TNBC, and HER2+) who undergo a baseline and 6-month screening MRI will be diagnosed with brain metastases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As we await these data, the existing evidence base, though limited, provides rationale to consider screening in patients at high risk of developing brain metastases and in situations where the knowledge of brain metastases status would impact the choice of systemic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central nervous system metastases: rising incidence with longer survival
“The incidence of brain metastases in breast cancer patients is increasing mainly due to improved systemic therapies resulting in more durable control of extracranial metastatic disease and prolonged survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease progression: shorter benefit from endocrine monotherapy after first line
“Although most HR-positive breast cancers benefit from first-line ET, most eventually become endocrine-resistant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second-line ET monotherapy has a median progression-free survival (PFS) of only 2–6 months, compared to 1–4 years for first-line ET” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment toxicities over sequential lines: assessment beyond adverse event frequency
“Assessment of treatment-related toxicity should extend beyond the frequency and severity of clinician-reported adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rates of treatment discontinuation due to toxicity should be considered alongside patient-reported outcomes (PROs) and validated measures of health-related quality of life, including the specific domains assessed and the completeness of their reporting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment toxicities over sequential lines: vasomotor symptoms and alopecia
“Vasomotor symptoms (VMS; also known as hot flashes) are common side effects of endocrine therapy, in particular in young women receiving LHRH analogs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Alopecia is a common distressing treatment toxicity that negatively impacts body image, quality of life and psycho-social functioning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, hair loss may occur with ADCs, CDK4/6 inhibitors and endocrine therapy (male-pattern androgenetic alopecia).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment toxicities over sequential lines: interstitial lung disease and cognitive impairment
“In the treatment of breast cancer, ILD has been associated with antibody drug conjugates, mTOR inhibitors, HER-2/EGFR targeted oral tyrosine kinase inhibitors, PD-1 or PD-L1 inhibitors, radiation therapy and rarely, CDK4/6 inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cognitive complaints are usually subtle or moderate, and most frequently related to ChT. However, other treatments, such as ET, targeted agents, and immunotherapy may also have an impact in cognitive function” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment toxicities over sequential lines: patient-reported side effects
“Patients with HR+/HER2- mBC experience substantial disease and treatment-mediated side effects, with low patient-physician concordance associated with worse HRQoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The only symptom that worsened in over 10% of the overall cohort was bone pain severity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer
Humanistic burden and health-related quality of life
Patient-reported symptoms, side effects, and quality of life in 321 participants with HR+/HER2- metastatic breast cancer in Europe and the United States
“Data were derived from the Adelphi Real World Advanced Breast Cancer Disease Specific Programme (DSP)™, a cross-sectional survey of physicians and their patients with HR+/HER2- mBC receiving treatment, conducted in Europe and the United States between August 2022 and February 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 298 physicians provided data on 1,642 patients, of which 321 patients self-reported data. Tiredness (85.6%), general worry (75.9%), and worry about future health (75.9%) were the most common patient-reported symptoms and side effects overall. Physicians reported bone pain (30.3%) and appetite changes (13.2%) as the most frequent patient symptoms, while estimating that most patients experienced no side effects (55.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with HR+/HER2- mBC experience substantial disease and treatment-mediated side effects, with low patient-physician concordance associated with worse HRQoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global health status and quality of life in 1250 participants receiving palbociclib plus endocrine therapy in the POLARIS real-world cohort
“Patients received palbociclib plus endocrine therapy as first-line, second-line or later line of therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Between January 2017 and January 2023, 1250 patients were enrolled and received ≥ 1 palbociclib dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For Question 29 (GHS), the proportion of patients with a favorable response significantly increased by ∼13% to 69.3% by month 6, which was maintained at month 12 (68.6%) and month 18 (70.0%). For Question 30 (QoL), the proportion of patients with a favorable response significantly increased by ∼9% to 74.5% by month 6, which was maintained at month 12 (75.0%) and month 18 (73.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pain and EQ-5D-3L utility by metastatic site and pain severity in 739 participants in the United States and Europe
“Overall, 173 oncologists and 739 patients participated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) health utility index was 0.73 (0.29) for the total population while the mean (SD) self-reported general health status was 62.0 (20.7)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was a significant difference in the mean health utility index related to metastatic sites, with mean (SD) index for patients with visceral and bone, bone only and visceral only metastases reported as 0.62 (0.33), 0.68 (0.34) and 0.78 (0.26), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients on chemotherapy reported significantly higher proportions of moderate/extreme levels of anxiety/depression (66.7%) and significantly lower general health status (60.7) compared with those on endocrine therapy (53.1% and 64.4, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Worst pain severity | Mean (SD) health utility index |
|---|---|
| Mild (1-4) | “0.81 (0.21)”View highlighted excerpt for this quote |
| Moderate (5-6) | “0.63 (0.27)”View highlighted excerpt for this quote |
| Severe (7-10) | “0.40 (0.45)”View highlighted excerpt for this quote |
Health-state utilities for stable, responding, and progressive disease: standard gamble study of 100 members of the UK general public
“One hundred members of the general public rated them using standard gamble to determine health state utility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stable disease on treatment had a utility value of 0.72, with a corresponding gain of +0.07 following a treatment response and a decline by 0.27 for disease progression. Toxicities lead to declines in utility between 0.10 (diarrhoea/vomiting) and 0.15 (febrile neutropenia).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The base state (stable disease with no side effects) had a utility value of 0.715. Moving to responding disease from stable on treatment produced a significant utility gain (+0.075). Moving from stable disease to progressive disease led to a significant decrement in utility (−0.272).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Structured review of health utility elicitation in advanced or metastatic breast cancer
“A total of 768 publications were identified in the searches, and 26 publications, comprising 18 journal articles and eight submissions to HTA bodies, were included in the evidence review.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the TTO-derived utilities for nine breast cancer health states were collected from two different cohorts, one in the Netherlands and one in Sweden. Of these, the Swedish sample rated progressive and stable disease health states (0.61 and 0.81, respectively) higher than the Dutch sample (0.49 and 0.69, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most submissions to HTA bodies obtained utility values from the literature rather than exploring the HRQOL data obtained during clinical development.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Symptom burden, activity impairment, and work productivity in 152 participants in the US VIRGO observational cohort
“This cross-sectional analysis evaluated baseline patient-reported outcomes (PROs) in patients with locally recurrent or metastatic breast cancer (MBC) receiving first-line hormonal therapy or chemotherapy and/or targeted therapy in the VIRGO observational study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 152 patients (chemotherapy cohort, 104; hormonal therapy cohort, 48) answered questionnaires. Fatigue, decreased sexual interest, disturbed sleep, emotional distress, and drowsiness were the most common severe symptoms, and were of moderate-to-severe intensity in 38.8%-52.0% of patients. Mean percent daily activity impairment was 30% for study patients, and WP impairment ranged from 20% to 40% across indices in employed patients (n, 58).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Time spent receiving health care during the first 3 months of treatment for metastatic breast cancer
“Average total time spent on health care ranged from 7% to 10% of all days included within the initial 3 months of treatment, depending on treatment. The greatest time contributions were time spent traveling for care and on inpatient services.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients receiving infusion/injection treatments, compared with those receiving oral therapy, spent more time in ambulatory care. Health care time was higher for patients receiving chemotherapeutic agents compared to those receiving hormonal agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient perspectives on progression-free survival and quality of life
“Virtual roundtables in Europe and the United States and interviews in Japan with breast cancer patients, patient advocates, and thought leaders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lengthened OS combined with no worsening or improvement in QoL remain the most important endpoints for mBC patients. Time when the disease is not progressing is meaningful to patients when coupled with improvements in QoL and no added treatment toxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported outcomes in EMBER-3: imlunestrant, imlunestrant plus abemaciclib, and fulvestrant or exemestane
“Most (72.3%) fulvestrant-treated patients reported injection site reactions at any time. Diarrhea frequency was consistently higher in the combination arm of imlunestrant–abemaciclib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GHS/QoL and function were maintained across treatment arms, despite a higher incidence of diarrhea in the imlunestrant–abemaciclib group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported outcomes in CAPItello-291: capivasertib plus fulvestrant versus placebo plus fulvestrant
“Median time to deterioration in EORTC QLQ-C30 GHS/QOL was 24·9 months (95% CI 13·8 to not reached) in the capivasertib-fulvestrant group and 12·0 months (10·2 to 15·7) in the placebo-fulvestrant group (hazard ratio [HR] 0·70, 95% CI 0·53 to 0·92).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Time to deterioration HRs for all EORTC QLQ-C30 and QLQ-BR23 subscale scores showed little difference between the treatment groups, except for diarrhoea, which was worse in the capivasertib-fulvestrant group than in the placebo-fulvestrant group (HR 2·75, 95% CI 2·01-3·81).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported outcomes in SOLAR-1: alpelisib plus fulvestrant versus placebo plus fulvestrant
“Time to 10% deterioration for Global Health Status/QoL was similar between arms (hazard ratio, 1.03; 95% CI, 0.72 to 1.48). Compared with placebo, deterioration in social functioning and in diarrhea, appetite loss, nausea or vomiting, and fatigue symptom subscales occurred with alpelisib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported outcomes in SERENA-6: switch to camizestrant at ESR1 mutation emergence during first-line therapy
“Switching to camizestrant-CDK4/6i delayed TTD and reduced the risk of deterioration in patient-reported cancer symptoms [pain (hazard ratio 0.57, 95% confidence interval 0.37-0.86), fatigue (0.75, 0.46-1.24), shortness of breath/dyspnoea (0.52, 0.28-0.93), breast symptoms (0.59, 0.28-1.24) and arm symptoms (0.69, 0.34-1.39)] and functioning [physical (0.74, 0.44-1.24), role (0.73, 0.48-1.10) and emotional (0.51, 0.29-0.87)] compared with AI-CDK4/6i.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life with first-line versus second-line CDK4/6 inhibitor use in SONIA
“HRQOL was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and EuroQoL 5-dimensions 5-level questionnaires at up to 11 time points over the course of both treatment lines (follow-up) until SONIA treatment discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No clinically or statistically significant differences in HRQOL were observed between treatment arms during follow-up. The estimated mean difference in FACT-B total score (CDK4/6i in second-line as reference) was -0.66 (95% confidence interval [CI] = -2.14 to 0.82; P = .39).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Health care resource utilization and costs per patient per month by line of therapy in 3203 premenopausal women with HR+/HER2- metastatic breast cancer, US commercial claims
“A total of 3203 patients received first-line, 2194 received second-line, and 1242 received third-line therapy for mBC. Mean number of IP days PPP6 M were 1.6, 1.3, and 1.5 days in the first, second, and third lines, respectively. Mean number of days with OP services PPP6 M was 31.4, 30.9, and 23.3 in the first, second, and third lines, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients receiving ET, mean total healthcare costs were $6521, $4440, and $4555 PPPM in the first, second, and third line, respectively. Among patients receiving chemotherapy, mean total healthcare costs were $16,842, $12,868, and $16,129 PPPM in the first, second, and third line, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
All-cause costs per patient per month and treatment patterns by line in 5563 privately insured participants with HR+/HER2- metastatic breast cancer before CDK4/6 inhibitors
“Among 5,563 eligible patients, endocrine therapy was the most common first-line (1L) therapy; its utilization trended downward from 63% (1L) to 23% (4L), with a simultaneous increase in chemotherapy use, 25% (1L) to 50% (4L).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average per patient monthly all-cause costs were $14,424. The 12-month indirect costs for short-term disability were substantially higher in MBC patients ($10,397) than in matched noncancer patients ($394).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Anticancer and supportive care drug costs by subtype in 15 215 participants in a US nationwide database, 2011 to 2021
“The mean total per-patient treatment and supportive care drug cost using publicly available Medicare prices was $334 812 for patients with HR-positive and ERBB2-positive MBC, $284 609 for patients with HR-negative and ERBB2-positive MBC, $104 774 for patients with HR-positive and ERBB2-negative MBC, and $54 355 for patients with TNBC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From 2011 to 2019 (most recent complete year 1 data are for patients diagnosed in 2019), annual costs in year 1 increased from $12 986 to $80 563 for ERBB2-negative and HR-positive MBC, $99 997 to $156 712 for ERBB2-positive and HR-positive MBC, and $31 397 to $53 775 for TNBC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, our study focused on outpatient treatment and did not account for other medical costs, such as surgery, radiation, imaging, and hospital stays.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resource utilization and costs in the year after first-line CDK4/6 inhibitor initiation in 901 Medicare-enrolled participants
“901 patients met the inclusion criteria with a mean age of 74 years (SD = 6.84). Nearly 24% (n = 214) had an IP admission in the 6 months following CDK4/6i initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Roughly 30% (n = 271) of patients had an ED visit, with a mean of 2.1 (SD = 1.54) visits per patient among those who had a visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean total health care costs over the 1-year period following CDK4/6is were $62,228 (95% CI = 52,281-73,029) per patient with the main drivers being OP services ($31,686 [95% CI = 27,168-36,925]) and pharmacy costs ($22,727 [95% CI = 19,273-25,931]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Projected lifetime health care costs after first-line CDK4/6 inhibitor plus aromatase inhibitor in a US Medicare-eligible population
“Total lifetime health care costs were also similar ($865,000 [95% CR = $807,400-$925,000], $866,800 [95% CR = $786,000-$965,000], and $901,000 [95% CR = $809,000-$1,004,600], respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All-cause medical costs and CDK4/6i drug costs were based on an analysis of patients aged 65 years and older in Optum Clinformatics DataMart.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost of disease progression in 5709 participants with metastatic breast cancer, US commercial and Medicare Advantage claims
“Of 5,709 patients with mBC, 3,707 patients with mCRC, and 5,201 patients with mLC, 56.8% of patients with mBC, 58.1% of those with mCRC, and 80.3% of those with mLC patients had evidence of disease progression over 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Per‐patient‐per‐month costs, which accounted for variable follow‐up time, were almost twice as high among progressors versus nonprogressors in patients with mBC, mCRC, and mLC. In each of the three cancer types, delays in progression were associated with lower health care costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
End-of-life costs and resource utilization in the last 6 months, 3878 participants in US commercial claims
“Of the 3,878 females included, 18.5% (n = 718) met the criteria for EOL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In adjusted analyses, the EOL cohort had 4.15 times higher 6-month total healthcare costs (EOL, $72,112 vs NEOL, $17,137; p < 0.001). NEOL month-to-month mean total healthcare costs fluctuated between $2336-$3145, while EOL costs increased steadily from $8,956 in the sixth month prior to death to $19,326 in the last month of life.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“EOL month-to-month costs increased precipitously in the last 2 months of life and were driven by acute inpatient care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cancer-attributable medical costs by phase of care and stage at diagnosis, SEER-Medicare
“Annualized average cancer-attributable costs for medical care (Medicare Parts A and B) and oral prescription drugs (Medicare Part D) were estimated by subtracting costs between cancer patients and matched controls. Costs are reported in 2019 US dollars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall annualized average costs were highest in the EOL-cancer death phase, followed by the initial and continuing phases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Breast cancer, stage at diagnosis | Initial phase | Continuing phase | End-of-life phase, cancer death |
|---|---|---|---|
| Distant, medical services (thousand 2019 US dollars) | “$67.4”View highlighted excerpt for this quote | “$22.3”View highlighted excerpt for this quote | “$91.9”View highlighted excerpt for this quote |
| All stages, medical services (thousand 2019 US dollars) | “$33.7”View highlighted excerpt for this quote | “$3.5”View highlighted excerpt for this quote | “$73.2”View highlighted excerpt for this quote |
Projected US prevalence and total medical and productivity costs of metastatic breast cancer, 2015 to 2030
“In 2030, we estimated there would be 246 194 prevalent cases of mBC, an increase of 54.8% from the 2015 estimate of 158 997. We estimated total costs (medical and productivity) of mBC across all age groups and phases of care were $63.4 billion (95% sensitivity range = $59.4-$67.4 billion) in 2015 and would increase to $152.4 billion (95% sensitivity range = $111.6-$220.4 billion) in 2030, an increase of 140%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health care contact days in the year after diagnosis among Medicare beneficiaries with metastatic breast cancer
“In the year after diagnosis, beneficiaries with colorectal cancer had the highest mean (SD) contact days (62.9 [48.1]), followed by those with lung (60.2 [47.0]), breast (48.7 [47.9]), and prostate (40.1 [42.4]) cancers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across all cancer types, mean contact days increased from 2008 to 2019 with a prominent increase in ambulatory days from 2016 onward; the largest increase in contact days was observed for breast cancer (44.9 [95% CI, 38.7-52.2] to 57.6 [95% CI, 46.9-70.8]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Encounter days in the first year of treatment among 2949 SEER-Medicare participants aged 67 years or older
“We assessed time toxicity using the number of encounter days patients interacted with the healthcare system per 100 days, within the first year of starting cancer treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with more than three comorbidities had significantly higher encounter days compared to those without comorbidities [RR 1.36 (95% CI 1.26, 1.46)]. Receipt of radiotherapy [RR: 1.45 95% CI (1.37, 1.54)] was associated with more encounter days compared to not receiving radiotherapy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of direct and indirect costs of breast cancer by stage
“Across cost categories, cost ranges tended to be higher in the US than any other country. Metastatic breast cancer was associated with higher costs than earlier-stage cancer. When indirect costs were accounted for, particularly in terms of productivity loss, they tended to be higher than any other estimated direct cost (e.g., diagnosis, drug, and other medical costs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase-specific costs per patient per month after first-line CDK4/6 inhibitor in 5435 participants, Japanese nationwide claims
“Among 5435 patients (median age 72.3 years), active treatment phases showed drug-dominated cost structures: first-line per-patient per-month (PPPM) cost was 482,936 Japanese yen (JPY) (drug 85%–90%), second-line 361,615 JPY (81%), and extended chemotherapy 255,922 JPY (66%). A marked inversion occurred in the palliative phase (PPPM 233,824 JPY; drug 11%, inpatient 70%) and terminal phase (PPPM 412,149 JPY; drug 17%, inpatient 69%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Death-anchored analysis of 1111 decedents identified a transition 2 months before death, when inpatient costs first exceeded drug costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer on families
Caregiver work changes and quality of life in 345 informal caregivers in the United States, United Kingdom, and Germany
“We conducted a one-time, cross-sectional survey of 345 informal caregivers of people living with mBC in the United States, United Kingdom, and Germany in December 2021.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One in three caregivers changed work status after onset of caregiving, either reducing working hours (12 %), stopping work altogether (13 %), or increasing working hours (8 %). Caregivers who reduced hours or stopped working reported better QoL overall with total CQOLC scores of 71.8 and 65.3, compared to those who maintained or increased work hours (CQOLC scores of 61.3 and 54.4, respectively, [p < 0.001]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Indirect costs of productivity loss for patients and family members, US employer claims
“The MarketScan Health and Productivity Management database (2005-2009) was used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MBC patients had more sick leave cost than controls ($2383 ± $5539 vs. $1282 ± $2083, p < 0.05). Controlling for covariates, MBC patients incurred 47% more short-term disability costs vs EBC patients (p = 0.009).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MBC patients' families incurred 39.7% (p = 0.06) higher indirect costs compared to EBC patients' families after controlling for key covariates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of cancer treatment and work productivity of patients and caregivers
“Of 978 potential citations, 62 articles or abstracts were included. Forty-six studies (74.2%) evaluated patient-related productivity; 10 studies (16.1%) focused on caregivers, and 6 studies (9.7%) were a combination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most commonly studied cancer was breast cancer (53.2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Metastatic patients’ family members had higher leave days and associated costs than matched patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Workdays missed and indirect costs among employees with newly diagnosed metastatic versus non-metastatic cancer, US claims
“The mean total number of days missing from work for patients with versus without metastases was 33.39 versus 14.91 (ratio = 2.40), 64.05 versus 27.15 (ratio = 2.36), and 105.93 versus 46.29 (ratio = 2.29) days within 3, 6, and 12 months after diagnosis, respectively. Estimates of indirect cost differences between the two groups ranged from $6,877 to $22,283 in the first year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Financial hardship by insurance status in 1054 women with metastatic breast cancer, US national survey
“Participants responded from 41 states (N = 1054; median age: 44 years). Overall, 30% were uninsured.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adjusted analyses, uninsured participants were more likely than insured participants to report contact by debt collectors (adjusted risk ratio [aRR]: 2.38 [2.06, 2.76]) and being unable to meet monthly expenses (aRR: 2.11 [1.68, 2.66]). Financial distress was reported more frequently by insured participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Young adult women with metastatic cancer reported a high burden of financial toxicity. Importantly, insurance does not protect against financial distress; however, the uninsured are the most materially vulnerable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Drivers of financial burden and cost-coping behaviors: qualitative interviews with patients and caregiver representatives
“A total of N=11 MBC patients or caregiver representatives participated in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both medical and non-medical costs drove financial burden among participants. All participants reported challenges navigating their health insurance and applying for financial assistance. Regardless of gaining access to assistance, financial burden persisted for nearly all patients and resulted in cost-coping behaviors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Even when MBC patients accessed assistance, excess financial burden persisted necessitating use of financial coping-behaviors such as altering medication use, maintaining employment, and taking on debt.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Financial toxicity in 145 women with metastatic breast cancer at a US outpatient clinic
“145 women with metastatic breast cancer receiving care at an urban outpatient breast cancer clinic.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Financial toxicity is common among women with metastatic breast cancer and more common among low-income women with the disease. In addition, financial toxicity is correlated with worse quality of life and overall cancer-related distress.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pooled rate of financial toxicity in breast cancer: meta-analysis of 66 studies
“Sixty-six studies involving 29 426 participants with breast cancer were enrolled in our study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled FT rate was 39.3% (95% CI, 32.4%-46.6%) in HICs and 72.3% (95% CI, 56.8%-83.8%) in LMICs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Medicare payment for liquid biopsy and tissue genomic sequencing panels, Clinical Laboratory Fee Schedule fourth-quarter file
| Code | Short description in the file | Rate in the file (U.S. dollars) |
|---|---|---|
| 0242U | “Trgt gen seq alys pnl 55-74” | “05000.00” |
| 0239U | “Trgt gen seq alys pnl 311+” | “03500.00” |
| 0326U | “Trgt gen seq alys pnl 83+” | “05000.00” |
| 81455 | “So/hl 51/>gsap dna/dna&rna” | “02919.60” |
Advanced Diagnostic Laboratory Test status and initial-period payment for Guardant360 CDx and FoundationOne Liquid CDx
| Test code | Laboratory | Test name | Payment amount during new ADLT initial period |
|---|---|---|---|
| 0242U | “Guardant Health, Inc.” | “Guardant360 CDx” | “$5,000.00” |
| 0239U | “Foundation Medicine, Inc.” | “FoundationOne Liquid CDx” | “$3,500.00” |
Medicare national coverage of next-generation sequencing companion diagnostics in advanced cancer
State biomarker testing insurance coverage laws
“Cost and lack of insurance coverage are common barriers to testing because insurance coverage varies across commercial payers, Medicare, and Medicaid.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen states have passed legislation related to biomarker testing since 2021” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All laws apply to commercial payers; in 12 states, the laws also apply to Medicaid.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most laws (n = 11) require coverage of biomarker testing broadly without regard to condition. Four states (Arkansas, California, Louisiana, and Nevada) specify coverage of cancer biomarkers, with California specifying coverage for testing for stage III or IV cancer only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Managed care perspectives on ESR1 and circulating tumor DNA testing costs and coverage
“Key insight: A primary consideration of payers in aBC is that the optimal biomarker testing parameters are uncertain, which leads to inconsistent testing practices and the need for management that promotes consistency while mitigating delays in care such as via treatment pathways.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants also recognized that although the cost of additional biomarker testing may not be realized by the provider or patient, it could be a cost-of-care consideration for payers including employer groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Payer participants expressed concern with regular, potentially costly testing if it does not result in actionable information for making treatment decisions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Coverage and out-of-pocket cost barriers to next-generation sequencing reported by US stakeholders in metastatic breast cancer
“This study revealed that despite the awareness and recognition of the value proposition of NGS-based molecular profiling in mBC, inconsistent payer coverage, high out of pocket costs for patients, and challenges in managing reimbursement and prior authorization processes can lead to suboptimal utilization of NGS, which can subsequently lead to suboptimal treatment decisions where approved therapies exist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interestingly, many payers (33%) were not aware of the current somatic biomarker testing recommendations from NCCN guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESR1 testing rates by line of therapy in US practice
“Testing rates at 1L initiation were 36.2% in endocrine-resistant MBC and 19.6% in endocrine-sensitive/de novo MBC. Testing rates were approximately 32% at second line and 25% at third line across subgroups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Specimen type and turnaround time of ESR1 tests during first-line therapy in US practice
“Among 7772 patients with mBC in the FHRD who initiated 1 L therapy, tumor ESR1 mutation status was evaluated for 222 (3%) patients at baseline (≤ 90 days before 1 L) and 1355 (17%) during 1 L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most (60%) tests during 1 L used tissue specimens, while the remaining 40% were liquid biopsies, and the median time from specimen collection to result reporting in 1 L was 28 (IQR:10–84) days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Oral selective estrogen receptor degraders and estrogen receptor degraders
Guideline recommendation: NCCN, elacestrant and imlunestrant for ESR1-mutated disease
Guideline recommendation: NCCN, imlunestrant plus abemaciclib and vepdegestrant
Guideline recommendation: ABC8, oral SERD class
“Since the approval of elacestrant based on the EMERALD trial [ 33 ], the class of oral SERDs has expanded with new agents now supported by phase 3 evidence. Across this body of evidence, a consistent pattern emerges of modest absolute clinical benefit in ESR1-mutated tumors, with hazard ratios generally in the 0.55–0.62 range.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Camizestrant showed encouraging results in the SERENA-6 trial using a ctDNA-guided switch strategy upon emergence of ESR1 mutations , though the clinical utility of treatment modification without radiological progression remains to be established [ 35 ].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The oral route of administration and generally favorable tolerability of these agents represent meaningful advantages for patients, particularly compared to intramuscular fulvestrant. Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline background: ASCO 2021, ESR1 testing before oral SERD approvals
“There are insufficient data at present to recommend routine testing for ESR1 mutations to guide therapy for HR-positive, HER2-negative MBC. Existing data suggest reduced efficacy of AIs compared with the selective estrogen receptor degrader fulvestrant in patients who have tumor or circulating tumor DNA (ctDNA) with ESR1 mutations (type: informal consensus; evidence quality: insufficient; strength of recommendation: moderate).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: elacestrant
Elacestrant, EMERALD: trial population and comparator
Elacestrant, EMERALD: progression-free survival
“PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; P = .002) and patients with ESR1 mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; P = .0005).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, 12-month PFS rates were 22.3% (95% CI, 15.2 to 29.4) versus 9.4% (95% CI, 4.0 to 14.8), respectively, in all patients versus 26.8% (95% CI, 16.2 to 37.4) and 8.2% (95% CI, 1.3 to 15.1), respectively, in patients with ESR1 mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Elacestrant, EMERALD: FDA review of the ESR1-mutated subgroup
“The median PFS was 3.8 months (95% CI, 2.2 to 7.3) in the elacestrant arm and 1.9 months (95% CI, 1.9 to 2.1) in the SOC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By contrast, the benefit-risk assessment in patients without ESR1 mutations was not favorable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Elacestrant, EMERALD: duration of prior CDK4/6 inhibitor therapy
Elacestrant, EMERALD: safety
“Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: imlunestrant
Imlunestrant, EMBER-3: FDA approval of monotherapy
Imlunestrant, EMBER-3: primary results
“Overall, 874 patients underwent randomization, with 331 assigned to imlunestrant, 330 to standard therapy, and 213 to imlunestrant–abemaciclib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the overall population, the median progression-free survival was 5.6 months with imlunestrant and 5.5 months with standard therapy (hazard ratio for progression or death, 0.87; 95% CI, 0.72 to 1.04; P = 0.12).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of grade 3 or higher adverse events was 17.1% with imlunestrant, 20.7% with standard therapy, and 48.6% with imlunestrant–abemaciclib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imlunestrant, EMBER-3: updated overall survival
“In patients with ESR1 m, median OS (mOS) was 34.5 months for imlunestrant versus 23.1 months for SOC [hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.43-0.86, P = 0.0043, boundary for significance not reached].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: vepdegestrant
Vepdegestrant, VERITAC-2: FDA approval
Vepdegestrant, VERITAC-2: primary results
“Among all the patients, the median progression-free survival was 3.8 months (95% CI, 3.7 to 5.3) with vepdegestrant and 3.6 months (95% CI, 2.6 to 4.0) with fulvestrant (hazard ratio, 0.83 [95% CI, 0.69 to 1.01]; P = 0.07).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events of grade 3 or higher occurred in 23.4% of the patients in the vepdegestrant group and in 17.6% of the patients in the fulvestrant group. Adverse events led to treatment discontinuation in 2.9% and 0.7% of the patients, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: camizestrant
Camizestrant, SERENA-6: first-line switch at ESR1 mutation detection
Camizestrant, SERENA-4: first-line trial in unselected patients
Giredestrant plus everolimus, evERA: primary results
“Patients were randomized 1:1 to giredestrant plus everolimus (giredestrant-everolimus) or standard endocrine therapy (i.e., exemestane, fulvestrant, or tamoxifen) plus everolimus (standard endocrine therapy-everolimus).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“median progression-free survival was 10.0 months with giredestrant-everolimus and 5.5 months with standard endocrine therapy-everolimus (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.27 to 0.54; P<0.001). In the overall study population, median progression-free survival was 8.8 versus 5.5 months, respectively (HR, 0.56; 95% CI, 0.44 to 0.71; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common adverse events in both groups were stomatitis (47.3% and 48.9%, respectively), diarrhea (26.9% and 22.6%), and anemia (23.6% and 21.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PI3K, AKT, and mTOR pathway inhibitors
Guideline recommendation: NCCN, PIK3CA, AKT1, or PTEN alterations
Guideline recommendation: ABC8, PI3K/AKT/mTOR pathway inhibitor class
“The EPIK-B5 trial confirmed that alpelisib + fulvestrant retains meaningful activity after CDK4/6i-based therapy in PIK3CA-mutated disease (median PFS improvement of 4.6 months; HR: 0.52), consolidating this combination as a valid option in the absence of contraindications [ 36 ].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gedatolisib, a multitarget PI3K/AKT/mTOR inhibitor, showed encouraging PFS results in the VIKTORIA-1 trial, but with a demanding administration schedule and significant stomatitis burden requiring careful management [ 39 ]. The use of a PI3K/AKT/mTOR inhibitor after progression on another agent of the same class is not recommended outside clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As multiple targeted agents are now available following progression on a CDK4/6i, the optimal sequence remains undefined; until prospective comparative data are available, the eligibility criteria of individual trials and the tumor biomarker profile should guide treatment selection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline recommendation: ASCO 2021, alpelisib and everolimus
“Alpelisib in combination with ET should be offered to postmenopausal patients in combination with fulvestrant, and to male patients, with HR-positive, HER2-negative, PIK3CA-mutated, ABC, or MBC following prior ET including an aromatase inhibitor (AI), with or without a CDK4/6 inhibitor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, everolimus may be an option in second or subsequent lines of endocrine-based therapy, although the clinical benefits in contemporary practice in patients treated with CDK4/6 inhibitors are not well defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There are no data for the use of alpelisib after everolimus, or vice versa, to guide clinical recommendations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Capivasertib, CAPItello-291: progression-free survival
“Overall, 708 patients underwent randomization; 289 patients (40.8%) had AKT pathway alterations, and 489 (69.1%) had received a CDK4/6 inhibitor previously for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the AKT pathway–altered population, the median progression-free survival was 7.3 months in the capivasertib–fulvestrant group, as compared with 3.1 months in the placebo–fulvestrant group (hazard ratio, 0.50; 95% CI, 0.38 to 0.65; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events leading to discontinuation were reported in 13.0% of the patients receiving capivasertib and in 2.3% of those receiving placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Capivasertib, CAPItello-291: biomarker-negative subgroup and overall survival
Comparator regulatory information: alpelisib
Alpelisib, SOLAR-1: progression-free survival and toxicity
“In the cohort of patients with PIK3CA-mutated cancer, progression-free survival at a median follow-up of 20 months was 11.0 months (95% confidence interval [CI], 7.5 to 14.5) in the alpelisib-fulvestrant group, as compared with 5.7 months (95% CI, 3.7 to 7.4) in the placebo-fulvestrant group (hazard ratio for progression or death, 0.65; 95% CI, 0.50 to 0.85; P<0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the overall population, the most frequent adverse events of grade 3 or 4 were hyperglycemia (36.6% in the alpelisib-fulvestrant group vs. 0.7% in the placebo-fulvestrant group) and rash (9.9% vs. 0.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentages of patients who discontinued alpelisib and placebo owing to adverse events were 25.0% and 4.2%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Alpelisib, SOLAR-1: overall survival
“In the PIK3CA-mutated cohort (n = 341), median OS [95% confidence interval (CI)] was 39.3 months (34.1-44.9) for alpelisib-fulvestrant and 31.4 months (26.8-41.3) for placebo-fulvestrant [hazard ratio (HR) = 0.86 (95% CI, 0.64-1.15; P = 0.15)]. OS results did not cross the prespecified efficacy boundary.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Alpelisib after a CDK4/6 inhibitor: BYLieve
Comparator regulatory information: inavolisib (first-line, endocrine-resistant disease)
Inavolisib, INAVO120: progression-free survival
“The median progression-free survival was 15.0 months (95% confidence interval [CI], 11.3 to 20.5) in the inavolisib group and 7.3 months (95% CI, 5.6 to 9.3) in the placebo group (hazard ratio for disease progression or death, 0.43; 95% CI, 0.32 to 0.59; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Inavolisib, INAVO120: overall survival
“After a median follow-up of 34.2 months in the inavolisib group and 32.3 months in the placebo group, the median overall survival was 34.0 months (95% confidence interval [CI], 28.4 to 44.8) with inavolisib and 27.0 months (95% CI, 22.8 to 38.7) with placebo (hazard ratio for death, 0.67; 95% CI, 0.48 to 0.94; P = 0.02 [prespecified boundary for statistical significance, P<0.0469]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events led to discontinuation of inavolisib in 6.8% of patients and discontinuation of placebo in 0.6%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inavolisib: NCCN limitation on sequencing
Comparator regulatory information: gedatolisib
Gedatolisib, VIKTORIA-1: safety
“Grade ≥3 treatment-related adverse events (TRAEs) reported in the gedatolisib-triplet and gedatolisib-doublet groups, respectively, included neutropenia (62.3%, 0.8%), stomatitis (19.2%, 12.3%), rash (4.6%, 5.4%), hyperglycemia (2.3%, 2.3%), and diarrhea (1.5%, 0.8%). Study treatment discontinuation because of TRAEs was reported in 2.3% (triplet) and 3.1% (doublet) of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: everolimus
Everolimus, BOLERO-2: progression-free survival and toxicity
“The most common grade 3 or 4 adverse events were stomatitis (8% in the everolimus-plus-exemestane group vs. 1% in the placebo-plus-exemestane group), anemia (6% vs. <1%), dyspnea (4% vs. 1%), hyperglycemia (4% vs. <1%), fatigue (4% vs. 1%), and pneumonitis (3% vs. 0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median progression-free survival was 10.6 months and 4.1 months, respectively, according to central assessment (hazard ratio, 0.36; 95% CI, 0.27 to 0.47; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Everolimus, BOLERO-2: overall survival
“Median OS in patients receiving EVE + EXE was 31.0 months [95% confidence interval (CI) 28.0–34.6 months] compared with 26.6 months (95% CI 22.6–33.1 months) in patients receiving PBO + EXE (hazard ratio = 0.89; 95% CI 0.73–1.10; log-rank P = 0.14).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CDK4/6 inhibitors after progression on a CDK4/6 inhibitor
Guideline recommendation: NCCN, another CDK4/6 inhibitor after progression
Guideline recommendation: ABC8, CDK4/6 inhibition beyond progression
“In view of the modest absolute benefit, the suboptimal control arm, and the availability of multiple biomarker-driven options in the post-CDK4/6i setting, the panel considers continued CDK4/6i beyond progression a less preferred strategy, reserving it for patients without access to other targeted therapies and in whom prior CDK4/6i benefit exceeded 12 months; when used, both the CDK4/6i and the endocrine agent should be changed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline recommendation: ASCO 2021, fulvestrant plus a CDK4/6 inhibitor
“Fulvestrant and a CDK4/6 inhibitor should be offered to patients with progressive disease during treatment with AIs (or who develop a recurrence within 1 year of adjuvant AI therapy) with or without one line of prior chemotherapy for metastatic disease, or as first-line therapy. Treatment should be limited to those without prior exposure to CDK4/6 inhibitors in the metastatic setting (type: evidence-based, benefits outweigh harms; evidence quality: high; strength of recommendation: strong).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Abemaciclib plus fulvestrant, postMONARCH: progression-free survival
“At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37% in the abemaciclib + fulvestrant and placebo + fulvestrant arms, respectively. These results were supported by BICR-assessed PFS (HR, 0.55 [95% CI, 0.39 to 0.77]; nominal P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with measurable disease, investigator-assessed ORR was improved with abemaciclib + fulvestrant versus placebo + fulvestrant (17% v 7%; nominal P = .015).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Abemaciclib plus fulvestrant, postMONARCH: overall survival
“Median OS was 32.1 months with abemaciclib plus fulvestrant versus 24.6 months with placebo plus fulvestrant (HR 0.80, 95% CI 0.60-1.06, P = 0.11, boundary for significance not reached).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Updated PFS was consistent with the primary analysis (HR 0.78, 95% CI 0.62-0.99, nominal P = 0.039).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ribociclib with switched endocrine therapy, MAINTAIN
“Of the 119 randomly assigned participants, 103 (86.5%) previously received palbociclib and 14 participants received ribociclib (11.7%). There was a statistically significant PFS improvement for patients randomly assigned to switched ET plus ribociclib (median, 5.29 months; 95% CI, 3.02 to 8.12 months) versus switched ET plus placebo (median, 2.76 months; 95% CI, 2.66 to 3.25 months) HR, 0.57 (95% CI, 0.39 to 0.85); P = .006.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 6 and 12 months, the PFS rate was 41.2% and 24.6% with ribociclib, respectively, compared with 23.9% and 7.4% with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Palbociclib continued with fulvestrant, PACE
“Palbociclib was the most common previous CDK4/6i (90.9%). The median PFS was 4.8 months on F and 4.6 months on F + P (hazard ratio [HR], 1.11 [90% CI, 0.79 to 1.55]; P = .62).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Imlunestrant plus abemaciclib, EMBER-3: combination arm
“Among 426 patients in the comparison of imlunestrant–abemaciclib with imlunestrant, the median progression-free survival was 9.4 months and 5.5 months, respectively (hazard ratio, 0.57; 95% CI, 0.44 to 0.73; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, most patients (65%) in the imlunestrant–abemaciclib group in our trial had received a CDK4/6 inhibitor previously, and the treatment effect of imlunestrant–abemaciclib (hazard ratio for progression or death, 0.51) in these patients was consistent with that in the overall population, and the median progression-free survival was 9.1 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imlunestrant plus abemaciclib, EMBER-3: ESR1-mutated subgroup in the approval
Imlunestrant plus abemaciclib: NCCN subgroup with prior CDK4/6 inhibitor
Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib: indirect treatment comparison
“Though not powered for formal hypothesis testing, PFS favored imlunestrant + abemaciclib versus fulvestrant + abemaciclib across all three ITC methods. Hazard ratios (95% confidence intervals) for Bucher, MAIC, and PSM were 0.77 (0.58-1.04), 0.77 (0.55-1.06), and 0.83 (0.56-1.22), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant, aromatase inhibitors, and tamoxifen
Guideline recommendation: NCCN, endocrine monotherapy
Guideline recommendation: NCCN, fulvestrant dose
Comparator regulatory information: fulvestrant
Comparator regulatory information: exemestane
OPERA-01 control arm: standard-of-care endocrine monotherapy
“Fulvestrant or the AIs letrozole, anastrozole, or exemestane (with gonadal suppression in pre- and perimenopausal women or men) are included as the physician’s choice of SOC ET monotherapy for the control arm. The SOC ET in the control arm aligns with the NCCN and ASCO guidelines recommending ET monotherapy as a treatment option to delay chemotherapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fulvestrant was recommended to patients who have not previously received fulvestrant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine monotherapy after a CDK4/6 inhibitor: EMERALD control arm
“However, the clinical activity of endocrine monotherapy in patients who have received prior CDK4/6 or mammalian target of rapamycin inhibition is limited, with a median progression-free survival (PFS) of approximately 2 months, highlighting a major unmet clinical need in the field.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SOC treatment was per investigator's choice of fulvestrant, anastrozole, letrozole, or exemestane monotherapy and dosed according to the labeling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine monotherapy after a CDK4/6 inhibitor: EMERALD control arm in ESR1-mutated disease
Fulvestrant or exemestane: EMBER-3 control arm outcomes
“Among 256 patients with ESR1 mutations, the median progression-free survival was 5.5 months with imlunestrant and 3.8 months with standard therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the overall population, the median progression-free survival was 5.6 months with imlunestrant and 5.5 months with standard therapy (hazard ratio for progression or death, 0.87; 95% CI, 0.72 to 1.04; P = 0.12).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant: VERITAC-2 control arm outcomes
“Among the 270 patients with ESR1 mutations, the median progression-free survival was 5.0 months (95% confidence interval [CI], 3.7 to 7.4) with vepdegestrant and 2.1 months (95% CI, 1.9 to 3.5) with fulvestrant (hazard ratio, 0.58 [95% CI, 0.43 to 0.78]; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among all the patients, the median progression-free survival was 3.8 months (95% CI, 3.7 to 5.3) with vepdegestrant and 3.6 months (95% CI, 2.6 to 4.0) with fulvestrant” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant: CAPItello-291 control arm outcomes
“In the overall population, the median progression-free survival was 7.2 months in the capivasertib–fulvestrant group, as compared with 3.6 months in the placebo–fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.51 to 0.71; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant: VIKTORIA-1 control arm outcomes
“The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine monotherapy in the second line: real-world progression-free survival
“the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The real-world effectiveness of current 2 L treatments post-1 L CDK4/6i are suboptimal, highlighting an unmet need for this patient population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PARP inhibitors for germline BRCA1 or BRCA2 variants
PARP inhibitor recommendations in second-line treatment: ESMO 2026 guideline
PARP inhibitor recommendation for hormone receptor-positive disease: ASCO 2021 guideline
PARP inhibitors versus nonplatinum chemotherapy in BRCA1/2 carriers: ASCO, ASTRO, and SSO 2020 guideline
“Platinum agents are recommended versus taxanes to treat advanced BC in BRCA carriers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and talazoparib) are preferable to nonplatinum single-agent chemotherapy for treatment of advanced BC in BRCA1/2 carriers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: olaparib
Comparator regulatory information: talazoparib
Prevalence of germline BRCA1 or BRCA2 variants in breast cancer: OlympiAD final analysis
“Approximately 5% of all breast cancer patients carry a germline deleterious mutation in BRCA1 and/or BRCA2 (BRCAm), with higher rates among those with human epidermal growth factor receptor 2 (HER2)-negative disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Olaparib versus chemotherapy: OlympiAD progression-free survival, response, and safety
“Of the 302 patients who underwent randomization, 205 were assigned to receive olaparib and 97 were assigned to receive standard therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio for disease progression or death, 0.58; 95% confidence interval, 0.43 to 0.80; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The response rate was 59.9% in the olaparib group and 28.8% in the standard-therapy group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The rate of grade 3 or higher adverse events was 36.6% in the olaparib group and 50.5% in the standard-therapy group, and the rate of treatment discontinuation due to toxic effects was 4.9% and 7.7%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Olaparib versus chemotherapy: OlympiAD final overall survival
“At 64% data maturity, median OS was 19.3 months with olaparib versus 17.1 months with TPC (HR 0.90, 95% CI 0.66–1.23; P = 0.513); median follow-up was 25.3 and 26.3 months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“receptor status (triple negative: 0.93, 0.62–1.43; hormone receptor positive: 0.86, 0.55–1.36)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While there was no statistically significant improvement in OS with olaparib compared to TPC, there was the possibility of meaningful OS benefit among patients who had not received chemotherapy for metastatic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Talazoparib versus chemotherapy: EMBRACA progression-free survival, response, and safety
“Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive standard therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median progression-free survival was significantly longer in the talazoparib group than in the standard-therapy group (8.6 months vs. 5.6 months; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The objective response rate was higher in the talazoparib group than in the standard-therapy group (62.6% vs. 27.2%; odds ratio, 5.0; 95% CI, 2.9 to 8.8; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Hematologic grade 3-4 adverse events (primarily anemia) occurred in 55% of the patients who received talazoparib and in 38% of the patients who received standard therapy; nonhematologic grade 3 adverse events occurred in 32% and 38% of the patients, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Talazoparib versus chemotherapy: EMBRACA final overall survival
“As the population was either triple-negative or hormone receptor-positive within EMBRACA, the effect of talazoparib on OS in these two subgroups was generally consistent, with HR 0.899 (95% CI 0.634–1.276) for triple-negative patients and HR 0.827 (95% CI 0.597–1.143) for hormone receptor-positive patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Altogether, a similar percentage of patients received subsequent systemic antineoplastic therapy in the talazoparib and chemotherapy groups (80.8% and 76.4%, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibody-Drug conjugates
Antibody-drug conjugate recommendations in third-line treatment and beyond: ESMO 2026 guideline
Antibody-drug conjugate positioning and sequencing: ABC8 consensus 2026
“In the ADC landscape, DESTINY-Breast06 showed that T-DXd can be an option for patients with HER2-low disease when the decision to initiate cytotoxic therapy is made, now earlier in the treatment sequence, as first-line cytotoxic therapy after progression on endocrine therapy and for whom further endocrine therapy was considered unsuitable, based on a 5.1-month improvement in median PFS over physician's choice chemotherapy (HR: 0.62), OS showed no statistically significant improvement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with HER2 ultra-low disease, the available data remain limited and further evidence is required before a recommendation can be made.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In view of the modest PFS improvement, the absence of mature OS data, the side effect profile, and the availability of other treatment options, Dato-DXd in this setting is not a preferred option at present.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sacituzumab govitecan has moved to a less favored position in this subtype following the negative results of ASCENT-07, which failed to demonstrate superiority over single-agent chemotherapy as first-line cytotoxic therapy in ER+/HER2-negative ABC (median PFS by BICR: 8.3 months in both arms; HR: 0.85)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the absence of validated predictive biomarkers and robust evidence from prospective clinical trials, routine sequencing of ADCs in this setting cannot currently be recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trastuzumab deruxtecan for HER2-low disease: ASCO 2022 rapid recommendation update
Sacituzumab govitecan for hormone receptor-positive disease: ASCO 2023 rapid recommendation update
Comparator regulatory information: trastuzumab deruxtecan
Comparator regulatory information: datopotamab deruxtecan
Comparator regulatory information: sacituzumab govitecan
Trastuzumab deruxtecan after chemotherapy in HER2-low disease: DESTINY-Breast04
“Of 557 patients who underwent randomization, 494 (88.7%) had hormone receptor–positive disease and 63 (11.3%) had hormone receptor–negative disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the hormone receptor–positive cohort, the median progression-free survival was 10.1 months in the trastuzumab deruxtecan group and 5.4 months in the physician’s choice group (hazard ratio for disease progression or death, 0.51; P<0.001) and overall survival was 23.9 months and 17.5 months, respectively (hazard ratio for death, 0.64; P=0.003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who had received previous treatment with CDK4/6 inhibitors, the median progression-free survival was 10.0 months in the trastuzumab deruxtecan group; without previous CDK4/6 inhibitor treatment, it was 11.7 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adjudicated, drug-related interstitial lung disease/pneumonitis occurred in 12.1% of the patients who received trastuzumab deruxtecan; 0.8% had grade 5 events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trastuzumab deruxtecan in HER2-low disease: DESTINY-Breast04 long-term survival
“For the HR+ cohort, the median OS was 23.9 months (95% CI 21.7–25.2) in the T-DXd arm and 17.6 months (95% CI 15.1–20.2) in the TPC arm (hazard ratio 0.69; 95% CI 0.55–0.87)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade ≥3 TEAEs occurred in 202 patients (54.4%) in the T-DXd arm and in 116 patients (67.4%) in the TPC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TEAEs associated with drug discontinuation were investigator-assessed interstitial lung disease (ILD) and/or pneumonitis at 10.2% in the T-DXd arm and peripheral sensory neuropathy at 2.3% in the TPC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trastuzumab deruxtecan after endocrine therapy in HER2-low or HER2-ultralow disease: DESTINY-Breast06
“Of the 866 patients who underwent randomization, 713 had HER2-low disease, and 153 had HER2-ultralow disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among the patients with HER2-low disease, the median progression-free survival was 13.2 months (95% confidence interval [CI], 11.4 to 15.2) in the trastuzumab deruxtecan group and 8.1 months (95% CI, 7.0 to 9.0) in the chemotherapy group (hazard ratio for disease progression or death, 0.62; 95% CI, 0.52 to 0.75; P<0.001); the results were consistent in the exploratory HER2-ultralow population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events of grade 3 or higher occurred in 52.8% of the patients in the trastuzumab deruxtecan group and in 44.4% of those in the chemotherapy group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adjudicated interstitial lung disease or pneumonitis occurred in 49 patients (11.3%; three events were grade 5 in severity) and in 1 patient (0.2%; grade 2), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Trastuzumab deruxtecan by time to progression on first-line CDK4/6 inhibitor: DESTINY-Breast06 subgroup analysis
“Median PFS (95% confidence interval) favored T-DXd versus TPC regardless of time to progression (TTP) on prior first-line endocrine therapy (ET) + cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i): <6 months: 14.0 (11.2-15.9) versus 6.5 (4.2-8.4) months for T-DXd versus TPC; 6-12 months: 13.2 (8.6-16.4) versus 6.9 (4.3-10.4) months; >12 months: 12.9 (9.8-17.1) versus 8.2 (6.9-10.9) months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Trastuzumab deruxtecan after endocrine therapy: FDA approval summary
“Random assignment was 1:1 to T-DXd or investigator's choice of chemotherapy (paclitaxel, nab-paclitaxel, or capecitabine).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The trial also met its key secondary end point, PFS by BICR in the overall population, with a HR of 0.64 (95% CI, 0.54 to 0.76, P < .0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This is the first indication specifying the category of HER2-ultralow expression in breast cancer, and an assay to select patients for this category was approved contemporaneously.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Datopotamab deruxtecan versus chemotherapy: TROPION-Breast01 progression-free survival and safety
“Patients were randomly assigned to Dato-DXd (n = 365) or ICC (n = 367).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS by BICR was 6.9 months (95% CI, 5.7 to 7.4) with Dato-DXd versus 4.9 months (95% CI, 4.2 to 5.5) with ICC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The rate of grade ≥3 treatment-related adverse events (TRAEs) with Dato-DXd was lower than ICC (20.8% v 44.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TRAEs (any grade; grade ≥3) were nausea (51.1%; 1.4%) and stomatitis (50%; 6.4%) with Dato-DXd and neutropenia (grouped term, 42.5%; 30.8%) with ICC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Datopotamab deruxtecan versus chemotherapy: TROPION-Breast01 final overall survival
“At data cut-off, median follow-up was 22.8 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“OS for the Dato-DXd versus ICC arm did not reach statistical significance (hazard ratio 1.01, 95% confidence interval 0.83-1.22, P = 0.9445).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Use of ADCs (trastuzumab deruxtecan and sacituzumab govitecan) as subsequent therapy was imbalanced: 12.3% in the Dato-DXd arm versus 24.0% in the ICC arm.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Datopotamab deruxtecan: FDA approval summary
“TB01 demonstrated a 2-month improvement in median PFS for Dato-DXd compared to ICC (6.9 months vs. 4.9 months, respectively; stratified hazard ratio (HR) 0.63 (95% CI: 0.52, 0.76; p<0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The OS endpoint was not met; at the final analysis (FA) of OS, the median OS was 18.6 months in the Dato-DXd arm and 18.3 months in the ICC arm (HR: 1.01, 95% CI: 0.83, 1.22).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most commonly reported adverse reactions (≥20%) with Dato-DXd were stomatitis, nausea, fatigue, alopecia, constipation, dry eye, keratitis, and vomiting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sacituzumab govitecan versus chemotherapy: TROPiCS-02 progression-free survival
“The median age was 56 years, 95% had visceral metastases, and 99% had a prior cyclin-dependent kinase 4/6 inhibitor, with three median lines of chemotherapy for advanced disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS was 5.5 months (95% CI, 4.2 to 7.0) with SG and 4.0 months (95% CI, 3.1 to 4.4) with chemotherapy; the PFS at 6 and 12 months was 46% (95% CI, 39 to 53) v 30% (95% CI, 24 to 37) and 21% (95% CI, 15 to 28) v 7% (95% CI, 3 to 14), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Key grade ≥ 3 treatment-related adverse events (SG v chemotherapy) were neutropenia (51% v 38%) and diarrhea (9% v 1%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sacituzumab govitecan versus chemotherapy: TROPiCS-02 final overall survival
“Overall survival was significantly improved with sacituzumab govitecan versus chemotherapy (median 14·4 months [95% CI 13·0-15·7] vs 11·2 months [10·1-12·7]; hazard ratio [HR] 0·79, 95% CI 0·65-0·96; p=0·020); survival benefit was consistent across Trop-2 expression-level subgroups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ORR was significantly improved with sacituzumab govitecan compared with chemotherapy (57 [21%] patients vs 38 [14%]; odds ratio 1·63 [95% CI 1·03-2·56]; p=0·035)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One fatal adverse event (septic shock caused by neutropenic colitis) was determined to be related to sacituzumab govitecan treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Chemotherapy
Chemotherapy recommendations in third-line treatment and beyond: ESMO 2026 guideline
Single-agent chemotherapy for endocrine-pretreated disease: ASCO 2021 guideline
“Patients with HR-positive human epidermal growth factor receptor 2-negative MBC for whom chemotherapy is being considered should be offered single-agent chemotherapy rather than combination chemotherapy, although combination regimens may be offered for highly symptomatic or life-threatening disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with HR-positive MBC with disease progression on an endocrine agent may be offered treatment with either endocrine therapy with or without targeted therapy or single-agent chemotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: capecitabine
Comparator regulatory information: eribulin
Comparator regulatory information: paclitaxel protein-bound
Eribulin versus treatment of physician's choice: EMBRACE
“762 women were randomly allocated to treatment groups (508 eribulin, 254 TPC).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall survival was significantly improved in women assigned to eribulin (median 13·1 months, 95% CI 11·8-14·3) compared with TPC (10·6 months, 9·3-12·5; hazard ratio 0·81, 95% CI 0·66-0·99; p=0·041).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Peripheral neuropathy was the most common adverse event leading to discontinuation from eribulin, occurring in 24 (5%) of 503 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Eribulin versus capecitabine: Study 301
“Median OS times for eribulin (n = 554) and capecitabine (n = 548) were 15.9 and 14.5 months, respectively (hazard ratio [HR], 0.88; 95% CI, 0.77 to 1.00; P = .056).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median PFS times for eribulin and capecitabine were 4.1 and 4.2 months, respectively (HR, 1.08; 95% CI, 0.93 to 1.25; P = .30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Objective response rates were 11.0% for eribulin and 11.5% for capecitabine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eribulin in hormone receptor-positive disease: pooled analysis of two phase 3 trials
Chemotherapy compared with endocrine-based therapy: network meta-analysis
“We identified 2689 published results and 140 studies (comprising 50 029 patients) were included in the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No chemotherapy or hormone therapy regimen was significantly better than palbociclib plus letrozole for progression-free survival.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, no chemotherapy regimen with or without targeted therapy is significantly better than CDK4/6 inhibitors plus hormone therapies in terms of progression-free survival.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Single-agent chemotherapy in the control arm of a contemporary trial: TROPION-Breast01
Chemotherapy after first-line CDK4/6 inhibitor in practice: systematic review of real-world evidence
Chemotherapy use and outcomes in second and third lines: SOLTI-1801 CDK-PREDICT
“In the second-line setting (n = 125), real-world therapeutic strategies included endocrine monotherapy (22%; n = 27), targeted therapies (51%; n = 65), capecitabine (10%; n = 12), and other chemotherapy agents (17%; n = 21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Targeted agents were frequent in 2L (51%) and capecitabine in 3L (36%), while endocrine monotherapy yielded poorest rwPFS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary: limitations of endocrine and targeted therapies after a CDK4/6 inhibitor
The oral estrogen receptor degraders approved after progression on endocrine therapy (elacestrant, imlunestrant, and vepdegestrant) are indicated for ESR1-mutated disease, and each label directs selection of patients “based on the presence of ESR1 mutation(s)” in a plasma specimen. Without ESR1 mutations, the progression-free survival hazard ratio for elacestrant was 0.86 (95% CI 0.63 to 1.19) in 250 participants (52%) in EMERALD, and median progression-free survival in EMBER-3 was 5.6 months with imlunestrant and 5.7 months with standard therapy (hazard ratio 1.00). In ESR1-mutated tumors, the ABC8 consensus describes “modest absolute clinical benefit” across the oral SERDs, with hazard ratios generally in the 0.55 to 0.62 range. In EMERALD, median progression-free survival was 2.8 versus 1.9 months in the overall population and 3.8 versus 1.9 months in the ESR1 mutation cohort. In the control arms of VERITAC-2 and EMBER-3, median progression-free survival was 2.1 months with fulvestrant among 270 participants with ESR1 mutations and 3.8 months with standard therapy among participants with ESR1 mutations, respectively. In real-world studies after a first-line CDK4/6 inhibitor, the weighted average median progression-free survival was 3.9 months with single-agent endocrine therapy and 6.1 months with chemotherapy, and in a second cohort, median second-line real-world progression-free survival with endocrine monotherapy was 5.0 months (n = 27).
Fulvestrant 500 mg is administered as two 5 mL intramuscular injections on Days 1, 15, 29, and once monthly thereafter, and injection site pain was reported in 11.6% of participants in the fulvestrant 500 mg group. Hyperglycemia was reported in 65% of participants treated with alpelisib, and increased fasting glucose occurred in 37% of participants treated with capivasertib and 85% of participants treated with inavolisib; adverse events led to discontinuation in 25.0% of participants receiving alpelisib (4.2% with placebo) and 13.0% of participants receiving capivasertib (2.3% with placebo). Overall survival was not significantly improved with capivasertib plus fulvestrant (hazard ratio 0.83 in the PIK3CA/AKT1/PTEN-altered subgroup), alpelisib plus fulvestrant in the PIK3CA-mutated cohort (39.3 versus 31.4 months), everolimus plus exemestane (31.0 versus 26.6 months), abemaciclib plus fulvestrant (32.1 versus 24.6 months), or imlunestrant in ESR1-mutated disease (34.5 versus 23.1 months, boundary for significance not reached). The ABC8 consensus does not recommend rechallenge with a second oral SERD or a second PI3K/AKT/mTOR inhibitor outside clinical trials, and states that following progression on a CDK4/6 inhibitor “the optimal sequence remains undefined”.
Summary: limitations of PARP inhibitors, antibody-drug conjugates, and chemotherapy
Olaparib and talazoparib are indicated for germline BRCA-mutated, HER2-negative disease, and approximately 5% of all breast cancer patients carry a germline deleterious BRCA1 and/or BRCA2 mutation. Neither improved overall survival significantly over chemotherapy: median overall survival was 19.3 months with olaparib and 17.1 months with chemotherapy (hazard ratio 0.90; 0.86 in hormone receptor-positive participants), and the overall survival hazard ratio with talazoparib was 0.827 in hormone receptor-positive participants. Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 12.1% of participants receiving trastuzumab deruxtecan in DESTINY-Breast04, and adjudicated interstitial lung disease or pneumonitis in 11.3% in DESTINY-Breast06; ocular adverse reactions occurred in 38% of participants treated with datopotamab deruxtecan in the pooled safety population; and grade 3 or higher treatment-related neutropenia occurred in 51% of participants receiving sacituzumab govitecan in TROPiCS-02. Overall survival with datopotamab deruxtecan was not significantly different from chemotherapy (hazard ratio 1.01), and the ABC8 consensus states that routine sequencing of antibody-drug conjugates in this setting “cannot currently be recommended”. In the TROPION-Breast01 control arm, single-agent chemotherapy produced a median progression-free survival of 4.9 months, with grade 3 or higher treatment-related adverse events in 44.7% of participants, and eribulin was not superior to capecitabine for overall survival (median 15.9 versus 14.5 months) or progression-free survival (4.1 versus 4.2 months).
ESR1 mutation restriction of oral endocrine therapy: elacestrant label
ESR1 mutation restriction of oral endocrine therapy: imlunestrant label
ESR1 mutation restriction of oral endocrine therapy: vepdegestrant label
No progression-free survival difference without ESR1 mutation: EMBER-3
“In exploratory analyses involving patients without ESR1 mutations, the median progression-free survival was 5.6 months in the imlunestrant group and 5.7 months in the standard-therapy group (hazard ratio for progression or death, 1.00; 95% CI, 0.79 to 1.27)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with ER-positive, HER2-negative advanced breast cancer, treatment with imlunestrant led to significantly longer progression-free survival than standard therapy among those with ESR1 mutations but not in the overall population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modest absolute benefit of oral SERDs: ABC8 consensus 2026
“Across this body of evidence, a consistent pattern emerges of modest absolute clinical benefit in ESR1-mutated tumors, with hazard ratios generally in the 0.55–0.62 range.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of a PI3K/AKT/mTOR inhibitor after progression on another agent of the same class is not recommended outside clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As multiple targeted agents are now available following progression on a CDK4/6i, the optimal sequence remains undefined; until prospective comparative data are available, the eligibility criteria of individual trials and the tumor biomarker profile should guide treatment selection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Short progression-free survival with endocrine monotherapy after a CDK4/6 inhibitor: EMERALD control arm
“Because of the initial drop in PFS in both arms, median PFS may not be a sufficient measure of efficacy in the overall population (2.8 months v 1.9 months) or ESR1 mutation cohort (3.8 months v 1.9 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a recent phase II trial, fulvestrant was associated with a median PFS of 1.9 months and a CBR of 13.7%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Short progression-free survival with fulvestrant after a CDK4/6 inhibitor: VERITAC-2 control arm
Short progression-free survival with standard endocrine therapy: EMBER-3 control arm
“Among patients with ESR1 mutations, the median progression-free survival was 5.5 months (95% confidence interval [CI], 3.9 to 7.4) in the imlunestrant group, as compared with 3.8 months (95% CI, 3.7 to 5.5) in the standard-therapy group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intramuscular administration of fulvestrant: fulvestrant label
Pharmacologic limitations of fulvestrant: review
“Clinical challenges with fulvestrant can be related to pharmacologic limitations, including the absence of oral bioavailability,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pharmacologic limitations regarding the bioavailability of fulvestrant have prompted strong interest in an orally bioavailable alternative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oral route compared with intramuscular fulvestrant: ABC8 consensus 2026
“The oral route of administration and generally favorable tolerability of these agents represent meaningful advantages for patients, particularly compared to intramuscular fulvestrant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gedatolisib, a multitarget PI3K/AKT/mTOR inhibitor, showed encouraging PFS results in the VIKTORIA-1 trial, but with a demanding administration schedule and significant stomatitis burden requiring careful management” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hyperglycemia with PI3K inhibition: alpelisib label
Hyperglycemia with AKT inhibition: capivasertib label
Hyperglycemia with PI3K-alpha inhibition: inavolisib label
Short real-world progression-free survival after first-line CDK4/6 inhibitor: US Flatiron cohort
“Cytotoxic chemotherapy was the most common second-line therapy, followed by endocrine monotherapy, administered to 249 (29.7%) and 104 (12.4%) of patients, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median rwPFS for those patients who received chemotherapy, fulvestrant monotherapy, or everolimus were 3.71, 3.25, and 3.32 months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Short real-world progression-free survival in second and third lines: SOLTI-1801 CDK-PREDICT
“Median rwPFS-2L was 5.0 months for endocrine monotherapy (n = 27), 7.0 months for targeted therapies (n = 65), 7.4 months for capecitabine (n = 12), and 8.7 months for other chemotherapy agents (n = 21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In rwPFS-3L, similar trends were seen (6.4 vs. 3.3 months; HR 1.74; 95% CI 0.98–3.08), with BL showing the poorest outcomes (HR 5.63; 95% CI 1.17–27.02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Endocrine monotherapy was consistently associated with the shortest rwPFS across lines, reinforcing its limited role in this setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Short real-world progression-free survival in second line: systematic review of real-world evidence
“The most assessed outcome was median rwPFS; the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“no studies reported disaggregated outcomes in the third-line setting or beyond” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The real-world effectiveness of current 2 L treatments post-1 L CDK4/6i are suboptimal, highlighting an unmet need for this patient population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall survival not statistically improved: EMBER-3 interim overall survival
“In patients with ESR1m, median OS (mOS) was 34.5 months for imlunestrant versus 23.1 months for SOC [hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.43-0.86, P = 0.0043, boundary for significance not reached].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall survival not statistically improved: PARP inhibitor trials
Overall survival not statistically improved: datopotamab deruxtecan
Overall survival not statistically improved: eribulin versus capecitabine
Inevitable endocrine resistance and uncertain sequencing: reviews
“Endocrine resistance inevitably develops in the metastatic setting, often mediated by acquired ESR1 mutations that promote ligand-independent ER activation and reduce sensitivity to standard antiestrogens.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Their optimal integration and sequencing in practice remain uncertain, and for tumors harboring dual ESR1 and PIK3CA mutations, with multiple biomarker-guided options available, the best treatment strategies are unclear.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With several oral SERDs emerging contemporaneously, data are needed to assess their relative efficacy, safety, and potential interchangeability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Resistance to anti-oestrogen therapy: review
Place in treatment, anticipated use, and care setting
Summary: anticipated place in therapy
Palazestrant has no approved indication. The company plans to submit a new drug application in 2027 for monotherapy in second- and third-line ER+/HER2- metastatic breast cancer and anticipates commercial launch in 2028. The FDA Fast Track designation covers ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. In OPERA-01, participants whose disease advanced after at least one endocrine therapy given with a CDK4/6 inhibitor are enrolled “regardless of ESR1 mutation status” and, in Part 2, randomized 1:1 to palazestrant 90 mg once daily or investigator's choice of standard-of-care endocrine therapy (fulvestrant, letrozole, anastrozole, or exemestane). The company states that “Palazestrant’s approval in ESR1 mutant and wild-type tumors in the 2/3L ER+/HER2- MBC setting would be paradigm-shifting”. The approved oral agents in the same setting, elacestrant, imlunestrant, and vepdegestrant, are each indicated only for ESR1-mutated disease after at least one line of endocrine therapy, and the NCCN guideline lists elacestrant, imlunestrant, or vepdegestrant for ESR1-mutated tumors, aromatase inhibitor monotherapy as a subsequent-line option, and fulvestrant with alpelisib or capivasertib for PIK3CA, AKT1, or PTEN alterations. The ESMO 2026 guideline states that at least two lines of endocrine-based therapy can be recommended before non-endocrine therapy in endocrine-sensitive disease and that a fulvestrant–CDK4/6 inhibitor switch or, to a lesser extent, fulvestrant monotherapy may be considered in the absence of targetable alterations. The ABC8 consensus recommends switching the endocrine mechanism of action when resistance emerges, reports oral SERD hazard ratios of 0.55 to 0.62 in ESR1-mutated tumors, and states that “Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials”. In one cohort treated after first-line CDK4/6 inhibitor therapy, second-line treatment was cytotoxic chemotherapy in 29.7% of 839 participants, endocrine monotherapy in 12.4%, and continued CDK4/6 inhibitor in 36.0%. Palazestrant is taken orally once daily, whereas fulvestrant is given as two intramuscular injections every 28 days, with injections “mainly requiring in-office administration”. The company plans a field force of approximately 75 to 100 representatives “to cover U.S. breast oncologists” and is studying palazestrant with ribociclib in the first line in OPERA-02, with the goal of positioning it as the “endocrine therapy of choice in the first-line setting”.
Proposed initial line of therapy: monotherapy in the second- and third-line setting
Company positioning for both ESR1-mutated and ESR1 wild-type tumors
Company estimates of United States incidence and market size in the second- and third-line setting
Planned commercial launch and prescriber audience
Company positioning as an endocrine backbone and first-line combination partner
Planned first-line use with ribociclib (OPERA-02)
Company description of endocrine sequencing in metastatic disease
ESMO guideline sequence for second-line and later endocrine-based therapy
ABC8 consensus on switching endocrine mechanism and oral SERD sequencing
“In general, when resistance emerges, switching the mechanism of action of endocrine therapy, with or without adding targeted treatment, is recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The oral route of administration and generally favorable tolerability of these agents represent meaningful advantages for patients, particularly compared to intramuscular fulvestrant. Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine-based regimens preferred after a CDK4/6 inhibitor
Oral once-daily administration and the outpatient care setting
Intramuscular fulvestrant requires in-office administration
Company description of fulvestrant administration
Real-world second-line treatment after first-line CDK4/6 inhibitor in the United States
“Cytotoxic chemotherapy was the most common second-line therapy, followed by endocrine monotherapy, administered to 249 (29.7%) and 104 (12.4%) of patients, respectively. Fulvestrant was the most commonly prescribed endocrine monotherapy (70 patients, 8.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three hundred two (36.0%) of patients continued a CDK4/6i.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world second- and third-line treatment after first-line CDK4/6 inhibitor in a European cohort
“In the second-line setting ( n = 125), real-world therapeutic strategies included endocrine monotherapy (22%; n = 27), targeted therapies (51%; n = 65), capecitabine (10%; n = 12), and other chemotherapy agents (17%; n = 21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the third-line setting ( n = 95), treatment options were more heterogeneous, including endocrine monotherapy (2%; n = 2), targeted therapies (29%; n = 27), capecitabine (36%; n = 34), other chemotherapy (26%; n = 25), and ADCs (7%; n = 7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of treatment effect
Palazestrant phase 2 results by ESR1 status at 120 mg (OP-1250-001)
Palazestrant results by ESR1 status in the second- and third-line subset (OP-1250-001)
Palazestrant plus ribociclib by ESR1 status after a prior CDK4/6 inhibitor (OP-1250-003)
Investigator interpretation of ESR1-dependent benefit across the class
“Recent studies showed that imlunestrant may be beneficial only for cancers harboring ESR1 mutations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limitations of this study, as with most early-phase clinical trials, include its open-label design and lack of a comparator arm that limit the interpretation of the observed safety profile and antitumor activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Elacestrant in tumors without a detected ESR1 mutation (EMERALD, FDA review)
“In an exploratory analysis of PFS in the ESR1-mut-nd subgroup, the HR was 0.86 (95% CI, 0.63 to 1.19), with the median PFS of 1.9 months (95% CI, 1.9 to 3.6) in the elacestrant arm and 2.0 months (95% CI, 1.9 to 2.2) in the SOC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By contrast, the benefit-risk assessment in patients without ESR1 mutations was not favorable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imlunestrant by ESR1 status (EMBER-3)
“In exploratory analyses involving patients without ESR1 mutations, the median progression-free survival was 5.6 months in the imlunestrant group and 5.7 months in the standard-therapy group (hazard ratio for progression or death, 1.00; 95% CI, 0.79 to 1.27)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, the treatment effect of imlunestrant–abemaciclib was similar in patients with or without ESR1 or PI3K pathway mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vepdegestrant by ESR1 status (VERITAC-2)
“Among all the patients, the median progression-free survival was 3.8 months (95% CI, 3.7 to 5.3) with vepdegestrant and 3.6 months (95% CI, 2.6 to 4.0) with fulvestrant (hazard ratio, 0.83 [95% CI, 0.69 to 1.01]; P = 0.07).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with ER-positive, HER2-negative advanced breast cancer, vepdegestrant was associated with significantly longer progression-free survival than fulvestrant in the subgroup with ESR1 mutations but not in the full patient population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Giredestrant plus everolimus by ESR1 status (evERA)
“Among 207 patients with ESR1 -mutated tumors, median progression-free survival was 10.0 months with giredestrant-everolimus and 5.5 months with standard endocrine therapy-everolimus (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.27 to 0.54; P<0.001). In the overall study population, median progression-free survival was 8.8 versus 5.5 months, respectively (HR, 0.56; 95% CI, 0.44 to 0.71; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consistency of oral SERD hazard ratios in ESR1-mutated tumors
Duration of prior endocrine therapy plus CDK4/6 inhibitor (EMERALD)
“In patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The P value for interaction between elacestrant treatment and prior ET+CDK4/6i duration (<12 vs. ≥12 months) was statistically significant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prior ET+CDK4/6i ≥12 months may help identify patients with ESR1-mutated tumors that remain endocrine-sensitive to elacestrant, enabling ET sequencing in the second line before other targeted therapies and drug combinations, and may delay chemotherapy-based regimens, including antibody–drug conjugates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concurrent ESR1 and PI3K pathway mutations with elacestrant in routine practice
“Disease with dual ESR1 and PI3K pathway mutations (PIK3CA, AKT1, and PTEN) had a median TTNT of 5.2 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Higher ESR1 polyclonality (≥4 alterations; 11% of patients) correlated with a shorter TTNT of 5.2 months (hazard ratio, 1.44; 95% confidence interval, 1.01–2.06), but efficacy was consistent across ESR1 alleles (e.g., Y537S and D538G).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visceral and bone metastases (EMERALD)
“ESR1 mutations are associated with visceral metastases and endocrine resistance” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this population, the median PFS (in months) for elacestrant versus SOC was 9.1 versus 1.9 (bone metastases), 7.3 versus 1.9 (liver and/or lung metastases)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visceral and liver metastases with elacestrant in routine practice
“In patients with coexisting ESR1- and PI3K-pathway–mutated tumors, mTTNT was 6.3 months (95% CI, 4.8–7.9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“mTTNT was 7.9 months (95% CI, 7.1–9.8) in all patients and was also sustained in patients with no prior fulvestrant [12.9 months (95% CI, 7.2–not reached)], no prior chemotherapy [8.4 months (95% CI, 7.1–13.3)], visceral metastasis [7.9 months (95% CI, 7.0–9.9)], and liver metastases [7.2 months (95% CI, 6.3–9.0)].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Abemaciclib plus fulvestrant across ESR1 and PIK3CA subgroups (postMONARCH)
“Consistent abemaciclib treatment effect was observed across the most prevalent biomarker subgroups” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HR, 0.79 (95% CI, 0.54 to 1.15) ESR1 detected versus 0.78 (95% CI, 0.54 to 1.12) not detected; HR, 0.76 (95% CI, 0.50 to 1.14) PIK3CA detected versus 0.80 (95% CI, 0.57 to 1.12) not detected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESR1 mutation prevalence by line of therapy
“ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients receiving 1st-line aromatase inhibitor + CDK4/6 inhibitor (n = 573) with ESR1mut had less favorable rwPFS and rwOS versus ESR1 wild-type; no differences were observed for fulvestrant + CDK4/6 inhibitor (n = 348).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
ESMO recommendation for ESR1 testing after progression on an aromatase inhibitor
ABC8 consensus on ctDNA testing at each progression and retesting
“The recommendation to test blood ctDNA at disease progression, provided that a targeted treatment is available, is consistent with the biology of ESR1 mutations as acquired mechanisms of endocrine resistance, their enrichment after aromatase inhibitor exposure, and the fact that plasma may better capture their polyclonal emergence than a single tissue biopsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The recommendation to consider tissue testing when plasma is negative, and to repeat testing under continued endocrine-based therapy if the result would influence treatment choice, is clinically sound and consistent with both regulatory developments and real-world clinic-genomic data” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ABC8 consensus against ctDNA as a test of disease progression
“We do not recommend ctDNA assessment for the demonstration of disease progression, while recognizing that ctDNA is an appropriate option to detect actionable genomic alterations for treatment selection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Liquid biopsy for acquired alterations in second and later lines
ESMO guideline interval for response assessment
Managed care practices for ESR1 testing and ctDNA monitoring
“A primary consideration of payers related to aBC is that the optimal biomarker testing parameters, including ctDNA-based monitoring for ESR1m aBC, are uncertain, which leads to inconsistent testing practices and the need for management that promotes consistency while mitigating delays in care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key insights include that community oncologists and patients may benefit from support, for example, with treatment pathways and patient navigators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior authorization practices suggested by managed care stakeholders
“They also indicated that many payers are already working to reduce prior authorization burden through practices such as auto-approvals (eg, for requests in concordance with biomarker testing guidelines), extending authorization duration (eg, from 12 to 24 months), and allowing gold carding, which relaxes prior authorization requirements for providers who have a demonstrated history of complying with coverage criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ASCO and ONS safety standards for oral antineoplastic therapy
“A subsequent 2013 revision expanded the standards to include the safe administration and management of oral chemotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The updated 2016 standards presented here include clarification and expansion of existing standards to include pediatric oncology and to introduce new standards: most notably, two-person verification of chemotherapy preparation processes, administration of vinca alkaloids via minibags in facilities in which intrathecal medications are administered, and labeling of medications dispensed from the health care setting to be taken by the patient at home.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ASCO and ONS 2024 standards update including home administration
“The standards presented here include clarification and expansion of existing standards to include home administration and other changes in processes of ordering, preparing, and administering antineoplastic therapy; the advent of immune effector cellular therapy; the importance of social determinants of health; fertility preservation; and pregnancy avoidance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adherence to oral anticancer therapy with a smartphone application (randomized trial)
“Study groups did not differ across any outcome measure, with an overall mean adherence of 78.81% (SD, 26.66%) per electronic pill caps.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although the mobile app may not improve outcomes for all patients prescribed oral cancer therapy, the intervention may be beneficial for those with certain risk factors, such as difficulties with adherence or anxiety.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adherence interventions for oral therapy in breast cancer (systematic review)
“Thirty-six studies met the inclusion criteria and involved a total sample of 28,528 BC patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The use of reminders, monitoring patients' medication-taking behaviors and giving feedback were the most frequently implemented techniques in those interventions that resulted significant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
CMS Enhancing Oncology Model scope for breast cancer
Other product development or post-marketing obligations required by the FDA
FDA alignment on the 90 mg dose for OPERA-01 Part 2 and OPERA-02
Randomized dose selection in OPERA-01 Part 1
“The Independent Data Monitoring Committee recommended a 90-mg palazestrant QD dose based on the available safety, efficacy, patient-reported outcomes, and pharmacokinetic data from participants treated with palazestrant 90 mg and 120 mg in Part 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Safety, efficacy, and PRO outcomes at the non-selected dose” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
REMS and post-approval requirements described by the company
Post-marketing requirements or commitments
Not applicable.
Ongoing post-approval monitoring
Post-approval safety reporting and surveillance described by the company
Post-approval monitoring requirements
Not applicable.
Expected outcomes of therapy
OPERA-01 planned primary endpoint
“The dual primary endpoint of the overall study is blinded independent committee review (BICR)-assessed PFS, defined as the time from randomization to the date of the first documented progression or death due to any cause, in participants with ESR1-mut and ESR1-mut-nd tumors, to be assessed separately.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company statement of the OPERA-01 design objective
Observed palazestrant monotherapy outcomes and stated expected benefit (OP-1250-001)
“In an analysis of 49 patients who received palazestrant as second- or third-line therapy with or without prior chemotherapy, the median PFS was extended to 7.2 months, with a CBR of 48% overall.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Palazestrant could result in prolongation of time on endocrine therapy, thereby increasing time to disease progression and delaying the transition to cytotoxic chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Standard endocrine therapy outcomes in the EMERALD control arm
“Accordingly, 6-month PFS rates were 34.3% (95% CI, 27.2 to 41.5) versus 20.4% (95% CI, 14.1 to 26.7) for the elacestrant versus SOC arms, respectively, in all patients and 40.8% (95% CI, 30.1 to 51.4) versus 19.1% (95% CI, 10.5 to 27.8), respectively, in patients with ESR1 mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant outcomes by duration of prior CDK4/6 inhibitor (EMERALD)
Standard endocrine therapy and imlunestrant outcomes in ESR1-mutated disease (EMBER-3)
Fulvestrant and vepdegestrant outcomes in ESR1-mutated disease (VERITAC-2)
“Among the 270 patients with ESR1 mutations, the median progression-free survival was 5.0 months (95% confidence interval [CI], 3.7 to 7.4) with vepdegestrant and 2.1 months (95% CI, 1.9 to 3.5) with fulvestrant (hazard ratio, 0.58 [95% CI, 0.43 to 0.78]; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant control arm outcomes in a PIK3CA wild-type population (VIKTORIA-1)
“The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant control arm outcomes after an aromatase inhibitor with or without a CDK4/6 inhibitor (CAPItello-291)
“Overall, 708 patients underwent randomization; 289 patients (40.8%) had AKT pathway alterations, and 489 (69.1%) had received a CDK4/6 inhibitor previously for advanced breast cancer. In the overall population, the median progression-free survival was 7.2 months in the capivasertib–fulvestrant group, as compared with 3.6 months in the placebo–fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.51 to 0.71; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant with and without abemaciclib after progression on a CDK4/6 inhibitor (postMONARCH)
“At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world progression-free survival with second-line therapy after first-line CDK4/6 inhibitor (systematic review)
“The most assessed outcome was median rwPFS; the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The real-world effectiveness of current 2 L treatments post-1 L CDK4/6i are suboptimal, highlighting an unmet need for this patient population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world progression-free survival with second-line therapy in the United States
Real-world second-line progression-free survival by treatment group in a European cohort
“Median rwPFS-2L was 5.0 months for endocrine monotherapy ( n = 27), 7.0 months for targeted therapies ( n = 65), 7.4 months for capecitabine ( n = 12), and 8.7 months for other chemotherapy agents ( n = 21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world time to next treatment with oral SERD monotherapy in ESR1-mutated disease
“The median TTNT was 6.4 months, and the time-to-treatment-discontinuation was 4.6 months. In those with ≤1 prior lines of metastatic therapy, the TTNT was 8.8 months, compared with 6.0 months in the third-line setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote